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Preface
This publication aims to support young doctors and surgery residents during their
training period. A surgical residency is a crucial period for a young doctor. A great
volume of theoretical information along with difficult and demanding practical 
skills need to be acquired in a relatively short period of time. Often, we are tempted 
to focus on specific pathologies, complex surgical interventions, or innovative
minimally invasive procedures and we skip the basic principles of a surgical act, 
which should be the pillar of further development. Consolidating basic notions and 
skills in surgery not only can help us learn and master different surgical steps and 
further complete interventions, but applied on time and correctly could represent a
saving gesture.
In the field of surgery, significant progress has been made in the last few decades
in both molecular and surgical pathology. Current research activity focuses more
and more on identifying and characterizing molecules that play a role in cancer
carcinogenesis, but also in finding new and effective therapeutic targets. Not least, 
many biomarkers have been studied in various types of cancer as predictors of
advanced stages of neoplastic disease or poor overall survival, but results are not
homogeneous.
This book is a tool for rapid, suitable acquisition of elementary surgical notions
and techniques, which represent the basis for training today’s resident to become
tomorrow’s surgeon.
Miana Gabriela Pop
‘Iuliu Hațieganu’ University of Medicine and Pharmacy,
Cluj-Napoca, Romania
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Introductory Chapter: General 




The history of surgery begins in antiquity, when various maneuvers were 
performed in order to treat injury and wounds. The results of these procedures were 
mostly characterized by increased rates of massive bleeding and severe infectious 
complications. An important role in surgery progress at that time has been the 
development of varied instruments which have begun to be used more and more in 
surgical practice. Initially characterized by elevated rates of postoperative mortal-
ity, surgery developed furthermore after the introduction, at the end of the nine-
teenth century, of aseptic and antiseptic methods.
Claudius Galen (129–200 AD) introduces for the first time the use of catgut for 
surgical sutures. Galen also made important contributions in the field of anatomy; he 
was the first to describe the anatomy of the recurrent laryngeal nerve [1]. Moreover, 
he demonstrated their importance in phonetics by cutting, in front of an auditory in 
Rome, the recurrent laryngeal nerves of a pig that remained afterward mute [1].
The first successful open appendectomy of an 11-year-old boy was reported, back 
in 1735, by Claudius Aymand (1681–1740), while the first laparoscopic removal of the 
appendix was realized in 1981 by Kurt Semm [2]. For years after, the gallbladder was 
removed for the first time through laparoscopy [3]. Before the introduction of laparo-
scopic techniques as a treatment option in various human pathologies, a large number 
of experimental interventions were performed on animals. Georg Kelling was the 
promoter of this learning technique, most of his experimental studies being per-
formed on dogs [4]. The first laparoscopic intervention was performed on a human in 
1910 by Hans Christian Jacobaeus and consisted of a “laparothoracoscopy” [5].
Due to the enthusiasm in terms of implementation of minimally invasive surgical 
techniques, natural orifice transluminal endoscopic surgery (NOTES) has been further 
developed. In 2004, the team lead by Dr. Kallo at the Johns Hopkins University reported 
the first NOTES procedure and demonstrated the feasibility of intra- abdominal 
exploration through the use of an endoscope [6]. Since then, the hybrid techniques 
have been developed as a combined endoscopic and laparoscopic approach [7].
After the revolution of laparoscopic procedures, robotic-assisted surgery was 
introduced in 1983, along with increasing interest in virtual reality [8]. Currently, 
there are several types of robotic systems (AESOP, EndoAssist, Neuromate, da 
Vinci, PROBOT (surgeon robot for prostatectomies), PAKY (robotic system for 
percutaneous access)), each with its advantages and disadvantages [8]. Some of the 
main advantages of robotic surgery are better three-dimensional (3D) vision and 
better ergonomics; the removal of psychological tremor while increase costs would 
represent the main disadvantage [9].
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The use of ultrasound in surgery or so-called interventional ultrasound has 
started in the 1960s and has been of great interest since then, developed in vari-
ous directions such as liver and pancreatic surgery and surgery of the biliary tract 
but also in cardiovascular surgery and neurosurgery [10]. Even if its importance 
in intraoperative guidance, accurate diagnosis, and decision-making has been 
demonstrated, no specific training programs in residency curriculum have been 
established so far [11].
Indocyanine green (ICG) absorbs near-infrared light and through this mecha-
nism allows for an accurate identification of the vascularization of different organs 
and tissues [12]. First used in cardiology to measure cardiac output and in ophthal-
mology to study in detail retinal vessels, in laparoscopic surgery ICG was used as a 
mean to improve vision [13]. Fluorescence-image-guided surgery (FISG) has been 
used in sentinel lymph node identification, in neurosurgery, or for neuroendocrine 
tumor detection. Moreover, the use of ICG in surgery has been shown to intervene 
in establishing the demarcation limit for surgical resection [12].
Development of mentoring programs through the use of telemedicine could 
be of great interest in the future from several points of view. First, by addressing 
this method, the difficulty in providing health care to people from disadvantage 
areas that do not have access to specialized, healthcare institutions could be over-
come [14]. Moreover, a highly specialized level of surgical act could be offered by 
surgeons with less experience in a particular field. Not least, telementoring could 
represent an important pylon of surgical training programs and development of 
surgical techniques.
Through the identification of various biomarkers in cancer pathology, the con-
cept of personalized medical and surgical treatment will be applied more and more 
in the future. Starting from this concept, patient treatment will need to be applied 
individually, depending on the molecular characteristics of the tumors. Surgical 
treatment will not represent a standardized procedure but one centered on patient 
needs and on its peculiarities.
For personalized surgery, 3D systems and the virtual surgical planning are 
important tools whose applicability are to be tested in the future more and more. 
The main advantage of these procedures consists in their ability to reproduce, with 
high accuracy, and patient’s anatomic characteristics and possible variants of a spe-
cific organ vasculature; this aspect allows improvement of the surgical procedure 
due to preoperative assessment of the surgical and technical plan to be applied [15]. 
So far, 3D systems and virtual surgical planning were mostly used in craniofacial 
surgery [15, 16].
All in all, there is a tremendous progress in the field of general surgery from its 
beginnings to the present. Efforts should be made to apply and develop modern 
available techniques in order to constantly improve surgical outcome and patient 
benefits.
Conflict of interest
No conflict of interest to declare.
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Stem Cell Markers in Colon Cancer
Miana Gabriela Pop
Abstract
Colon cancer incidence is increasing in young people. Even if, so far, colon 
cancer had a maximum incidence in the sixth and seventh decades of life, lately 
its incidence in people age 50 and younger is increasing. Thus, colon cancer still 
represents a major health problem despite constant research made in the field. Early 
detection of colon cancer is mandatory for an appropriate treatment of the disease 
and to attain increased overall survival. Even if various stem cell markers have been 
studied in order to evaluate their prognostic value in colon cancer cases, results in 
literature are heterogeneous, and no clear consensus has been drafted so far. This 
paper aims to review the most important stem cell markers identified in colon 
cancer and to establish their role in both cancer diagnosis and progression.
Keywords: colon, cancer, stem cell markers, CD133, CD44, CD166, EpCAM
1. Introduction
Colon cancer is a frequent neoplastic disease which is ranked second in female 
after breast cancer and third in men after prostate and lung and cancer [1]. Despite 
constant research in the field of colon cancer, its incidence continues to be high 
worldwide. Moreover, the number of people age 50 or younger diagnosed with 
colon cancer is dramatically increasing in last years. This finding upholds the idea 
that colon cancer is not a disease considered to be under control at this time, and 
efforts should be made in order to better understand its pathogenic mechanism.
Five-year overall survival in colon cancer ranges from 90% in early stages to less 
than 10% in advanced, metastatic cases [2]. It is thus important to try to diagnose 
the disease in early stage, so an appropriate treatment can be applied. Achieving this 
condition can be difficult, considering the fact that a large number of colon cancer 
patients present with late stage, often inoperable tumors.
Even if important progress has been made in terms of imaging diagnosis of colon 
cancer, early detection is still difficult to achieve. An important role in detecting 
early colon cancer cases is assigned to screening programs that have to be applied 
nationally, and population should be well informed of their importance. More than 
detecting incipient cases, early detection of advanced cases is also of crucial impor-
tance, and efforts should continue in this direction by further research groups.
Colon cancer stem cells (CCSCs) are multipotent neoplastic cells that have 
the ability to differentiate and initiate the carcinogenesis process [3]. Due to their 
increased viability, CCSCs are responsible for both tumor growth and tumor recur-
rence [4, 5]. According to a recent study, the presence of CCSCs is also responsible 
for resistance to chemotherapeutic treatments, which is observed in some cases [5]. 
A new treatment concept linked to CCSCs is based on their early detection, before 
the onset of the tumor, which would allow them to target with apoptotic substances.
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Detection of cancer stem cells (CSCs) in various digestive and extra-digestive 
cancers has been a topic of great interest in the literature of recent years and was 
frequently done using cluster of differentiation (CD) markers. In colon cancer, 
various biomarkers have been identified at the surface of CSCs, and their role in 
colon cancer is currently being tested: EpCAM, CD133, CD29, CD24, CD44, CD166, 
ALDH1A1, and ALDH1B1 [3, 4].
The aim of this paper is to review the most important biomarkers which have 
been identified in colon cancer, to expose current information regarding their role 
in colon cancer development and progression and to identify possible predictive 
biomarkers for advanced stages of the disease.
2. CD133/prominin-1
CD133 was first described in 1997 by Yin et al. on the cellular surface of 
hematopoietic cells [6]. Also called prominin-1, CD133 is a 5-transmembranaire 
glycoprotein of 120 kDa which can be found in two isoforms: CD133-1 and CD133-2 
[5–7]. CD133 is found on the short arm of chromosome 4 [5]. Its cellular function 
is unclear [5–7], but its involvement in cell-cell and cell-matrix interactions was 
described [5]. According to some recent studies, CD133 expression is an important 
tool in cancer stem cells (CSCs) identification and characterization [7]. CD133 was 
found to be expressed in various digestive (pancreatic, liver, colorectal) and non-
digestive tumors (brain, kidney, prostate, ovary cancer) [7–9]. CD133 expression 
promotes cancer cell proliferation through activation of Wnt/beta-catenin pathway 
[10, 11]. Moreover, in highly expression CD133 cancer stem cells, the development 
of solid tumor mass is assured by the anti-apoptotic factors BCL-2, BCL-XL, and 
MCL-1 that are stimulated through PI3K pathway, with subsequent activation of 
Akt [11]. Even if various studies focused on targeting CSCs and especially CD133 
due to its overexpression, most of the results arise from in vitro research and not 
from clinical experience. Targeted therapy was tested using Anti-CD133 scFv 
immunotoxins by Waldron et al. that found an interruption of the protein synthesis 
secondary to this process [12].
CD133 expression in colon cancer was confirmed 10 years after its initial descrip-
tion in 2007 [13, 14], when Obrien et al. proved that neoplastic cells expressing 
CD133 have the ability to form solid colon cancer masses in immunodeficient mice. 
From that point, many studies focused on CD133 expression in colon cancer car-
cinogenesis. Various studies analyzed CD133 expression in relation to clinical and 
pathological characteristics of the neoplastic patients, but result were inconsistent. 
CD133 expression correlates with the degree of tumor wall involvement (T) [15], 
with distant metastasis formation (M) [5, 16], with venous (V) and lymphatic (L) 
invasion [15]. A relation between CD133 expression and tumor recurrence was also 
noticed in one study [5], while other research groups found a significant association 
between CD133 expression and tumor size [7]. CD133 expression was correlated in 
some studies with a poor degree of tumor differentiation (G) [7], but the result was 
not confirmed by other studies where CD133 expression was found more frequent in 
moderate (G2) and well differentiated (G1) colon tumor tissues [17].
Chemoresistance was also found to be influenced by CD133 expression in colon 
cancer especially due to upregulation of FLICE-like inhibitory protein (FLIP), a 
ligand that inhibits tumor necrosis factors (TNF)-mediated apoptosis [11]. According 
to some studies, tumors expressing CD133 are more likely to be resistant to chemo-
therapy [5, 7, 18]. Moreover, tumors expressing high CD133 and CD44 biomarkers on 
the cellular surface are expected to be unresponsive to chemotherapy when compared 
to tumors where the expression of the two molecules is low or absent [16].
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Results are contradictory in terms of CD133 expression in liver metastases 
secondary to colon cancer. While CD133 expression in liver metastases was thought 
to predict a better overall survival (OS) in colon cancer patients [19], Spelt et al. 
found, in a recent study, different results [4]. According to them, CD133 expression 
in liver metastases is associated with worse overall survival (OS). Results in favor 
of a worse prognostic impact of CD133 expression in liver metastases are suggested 
also by Narita et al. which demonstrated an increased CD133 expression in cases of 
early recurrence of liver metastases compared with a low CD133 expression in late 
recurrent liver metastases [20].
In terms of survival, overexpression of CD133 was associated with worse overall 
survival in some studies [16, 21–23] and also with low disease-free survival interval 
[23], but the relation was not found by others [4, 5, 17, 24, 25]. According to two 
recent meta-analyses, CD133 expression represents a negative prognostic factor in 
colon cancer patients [23, 26].
Heterogeneous results exist in literature considering CD133 role in colon cancer. 
Its involvement in tumor progression and metastasis formation is suggested, but its 
precise role remains unclear. CD133 represents a useful tool for CSCs identification 
and characterization in colon cancer samples. Various studies analyzed the cor-
relation between CD133 expression and clinical and pathological characteristic of 
the patient, but a direct association between its degree of expression and advanced 
tumor stages was not confirmed. Moreover, its prognostic role regarding overall 
survival in colon cancer is still debated, and further studies are needed for a better 
characterization of the molecule in relation to colon cancer patients.
3. CD44 in colon cancer
CD44 is a type 1, 85–200 kDa transmembrane glycoprotein expressed in both 
normal and tumor tissues [16, 27, 28]. Discovered initially as a receptor for hyal-
uronic acid, the molecule has retained its affinity for it and for other components 
like collagens, osteopontin, or type I metalloproteinase [3, 27]. Supplementary, an 
adhesion function was highlighted for CD44 that was found to intervene in both 
cell-cell and cell-matrix interactions [4, 16]. From a structural point of view, CD44 
has three main domains: an extracellular one, a transmembrane, and, respectively, 
an intracellular domain [27]. CD44 has the capacity to present in various isoform, 
depending on the exons that attach to the extracellular part (CD44v) [27]. Its 
encoded gene is located on the short arm of chromosome 13 [29].
CD44 is expressed ubiquitary in normal tissue and participates, through lympho-
cytes activation, in various inflammatory processes [3, 27]; its involvement in wound 
healing processes was also described by some authors [3]. In neoplastic lesions, CD44 
is expressed, in different isoforms, in pancreatic (CD44v8–10) and colon cancer 
(CD44v6) [27], in prostatic tumors (CD44s—standard isoform), in breast cancer [27], 
and also in epithelial ovarian cancers [30]. Through its adhesiveness properties, CD44 
was found to intervene in tumor growth [16, 17]. Additionally, tumor cells expressing 
CD44 present with invasiveness properties and are also characterized by the capacity 
to initiate the metastatic process [28, 31] intervening thus in cell differentiation, pro-
liferation, and migration [32]. The mechanisms by which the molecule intervenes in 
these processes remain, however, unknown, and further studies have to be performed.
Assessment of the prognostic value of CD44 was analyzed in recent papers that 
highlighted an association between CD44 expression and both advanced tumor 
stages and liver metastasis formation [27, 31]. Overexpression of CD44 in colon 
cancer samples was found to negatively influence overall survival of colon cancer 
patients [33, 34]; one study group found a negative association between CD44 
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cancer samples was found to negatively influence overall survival of colon cancer 
patients [33, 34]; one study group found a negative association between CD44 
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expression and poor overall survival only for a specific variant of CD44 and, respec-
tively, Cd44v2 [35]. The association between upregulation of CD44 in colon cancer 
and worse overall survival was not confirmed by other study groups [24, 36], but the 
analysis was completed based on standard isoform of CD44 (CD44s). CD44 usage 
as an independent prognostic factor in colon cancer patients is not currently recom-
mended [17], but further studies need to concentrate on specific isoforms, like the 
one abovementioned, in order to correctly identify its value as a prognostic marker.
CD44 targeting is currently being tested in various digestive (stomach, colon can-
cer) [31, 37] and non-digestive cancer (lung, breast cancer) [38]. The results in terms 
of cancer stem cell apoptosis for in vitro and preclinical animal models are promising. 
In pancreatic cancer the anti-CD44 antibody tested against CD44v6 isoforms with 
promising antitumor results was bivatuzumab [37], while the first humanized anti-
body directed toward solid tumors expressing CD44 approved for clinical research is 
RO5429083 (NCT01358903), and the publication of results is in progress.
4. CD24 in colon cancer
CD24 is a glycoprotein located on the external surface of the cellular membrane 
[16]. It is formed of 27 amino acids, and it has a molecular weight of 24–70 kDa  
[5, 26]. Its expression was confirmed in normal nervous tissue [16] and in cancers 
of the colon [5], pancreas [24], breast, and prostate [26]. CD24 is involved in 
cellular signaling processes, in cellular differentiation, and in proliferation and is 
being considered a significant marker of cancer stem cells (CSCs) [4, 16, 39]. The 
mechanism by which CD24 participates in signaling processes seems to be related to 
mitogen-activated protein kinase (MAPK) and serine/threonine pathway [26].
In colon cancer, CD24 was found to be expressed in a percentage of 50–68%  
[24, 40]. CD44 is involved in first steps of carcinogenesis and plays an important 
role in liver metastasis formation [4, 9, 41–43]. Yeo et al. found CD24 a useful 
diagnostic marker of early colon cancer [39], whereas its expression was higher in 
malignant polyps than CD24 expression in colon adenomatous lesions.
No correlation was found between CD24 expression in colon cancer and tumor 
type or degree of differentiation (G) [5, 44]; other authors have highlighted, 
however, an inverse relation between CD24 expression and tumor size, poor 
differentiated cancers, and advanced TNM stages [39]. Regarding lymph node 
involvement and CD24 expression, as association between high CD24 expression 
and a larger number of lymph nodes involved was reported in some research papers 
[45] but not in others [5, 24]. In terms of overall survival, CD24 expression was in 
general associated with worse survival rates [16, 26]; results were not confirmed by 
other recent research papers [5, 24, 44]. Resistance to chemotherapeutic treatment 
was also objective by Nosrati et al. [5] probably due to their capacity to induce the 
epithelial-mesenchymal transition (EMT) mechanism [46]. Moreover, colon cancer 
stem cells expressing both CD133 and CD24 markers were found to be resistant to 
chemotherapeutic regiments based on 5-FU [47].
CD24 was highly studied in colon cancer samples, but consistent results have 
failed to establish its precise role in colon cancer, considering the heterogeneous 
results observed.
5. Epithelial cell adhesion molecule (EpCAM)
Epithelial cell adhesion molecule (EpCAM) is a Ca2+ independent, type I 
transmembrane glycoprotein with a molecular weight of 40 kDa [48] located on 
13
Stem Cell Markers in Colon Cancer
DOI: http://dx.doi.org/10.5772/intechopen.84315
the basolateral surface of epithelial tissues [49]. EpCAM expression was not seen in 
mesenchymal or lymphoid tissues [50]. EpCAM presents with two main domains: 
EpICD, an intracellular domain, and EpEx, an extracellular domain of 26, respec-
tively, and 242 amino acids [48, 51].
EpCAM was found to be overexpressed in various digestive (stomach, colon, 
pancreas, and esophagus) and non-digestive (prostate, ovary, breast) cancers [49]. 
EpCAM is principally involved in adhesion processes, but its role in cellular differ-
entiation and progression was also confirmed [50].
A high percentage of colon cancer cases (79–99.7%) is characterized by over-
expression of EpCAM molecule at tumor level [52, 53]. Moreover, EpCAM was 
found to be expressed also in liver metastases secondary to colon cancer, a situation 
that confirmed its involvement in cancer progression as well [50, 52]. Normal liver 
parenchyma does not express EpCAM [54].
Overexpression of EpCAM in colon cancer correlates in some studies with 
advanced stages of the disease [50, 55, 56], with a higher risk of metastases [55, 56], 
with poor differentiated (G3) patterns [54–57], with the number of lymph nodes 
involved (N) [48, 54], and with perilymphatic (L) and perivenous (V) invasion 
[54, 57] but also with worse overall survival [55, 56]. The results were not, however, 
confirmed by other study groups, so the predictive value of EpCAM in colon cancer 
patients was difficult to establish [58].
EpCAM is also involved in epithelial-mesenchymal transition (EMT) process 
[56]. During EMT, neoplastic cell detaches from the primary tumor (due to loss 
of EpCAM expression and less intercellular adhesions) to enter the lymphatic and 
vascular system and initiate the carcinogenesis process [56]. Detached cells, also 
called circulating tumor cells (CTCs), can be identified from blood samples through 
“liquid biopsy” technique that is based also on EpCAM detection using specific 
anti-EpCAM antibodies [59, 60].
In order to achieve distant metastasis formation, circulating tumor cells have 
to undergo a second, reversed process called mesenchymal-epithelial transition 
(MET) during which an upregulation of EpCAM expression at the cellular surface 
has been observed [59]. Secondary to it, cells acquire adhesion properties that allow 
them to form a solid metastatic mass [59].
Despite constant research in the field of cancer stem cell biomarkers in colon 
cancer, specific factors or local conditions that initiate and promote EMT or MET 
are insufficiently known, and further research have to be performed.
6. CD166 or ALCAM
CD166, also called activated leukocyte cell adhesion molecule (ALCAM), is 
a 110 kDa, transmembrane type-1 glycoprotein used for colon cancer stem cell 
(CCSC) identification [3, 61, 62]. Providing the leukocyte receptor function, 
CD166 expression was identified in both normal and colonic tissue, in the latter 
cases the expression being superior [3, 63]. CD166 expression in colon cancer varies 
between 58.6 and 76% [64, 65] and is higher in colonic adenomas [66], suggesting 
its involvement in colon carcinogenesis. Due to its adhesive properties, CD166 is 
considered to be involved in colon cancer tumor growth [62]. CD166 expression 
was also confirmed in pancreatic, esophageal and gastric, prostate, melanoma, and 
breast cancers [63].
Expression of CD166 in colon cancer was studied in relation to tumor stage 
[61, 64, 65], lymph node involvement [61, 64], or degree of cellular differentia-
tion (G) [61], but even if overexpression was confirmed, no statistic significant 
correlation was found. Regarding overall survival of colon cancer patients, 
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overexpression of CD166 failed to predict its outcome. Some literature stud-
ies found a worse overall survival in colon cancer cases characterized by high 
CD166 expression [64]. Levin et al. found that even the survival was reduced 
by 15 months for patients who presented colon tumors characterized by high 
CD166 expression compared with tumors with low or absent CD166 expression 
[67]. Other studies could not establish the prognostic relation of CD166 in colon 
cancer patients [65].
Limited number of studies analyzed CD166 expression in colon cancer patients, 
and existing results are inconclusive. Therefore, the role of CD166 in colon cancer 
remains unclear.
7. CD29
Through CD29 molecule, also known as integrin β1, cells adhere to extracellular 
compartment proteins and facilitate intracellular transmission of the cellular signal 
[68]. CD29 presents with 3 structural domains, the extracellular one being best 
represented [69].
Expression of CD29 was observed in normal and tumor colonic tissues, and a 
presumptive role in cellular differentiation was attributed to it, due to the activation 
of Erk signaling pathway [68, 69]. In normal colonic mucosa, CD29 is expressed in 
the lower part of the intestinal crypt [69] and is considered to be involved in intesti-
nal proliferation [68]. However, its precise role in colon cancer is unknown [68].
At present, CD29 expression in colon cancer is only used as diagnostic marker 
for CSCs. Further studies are needed to evaluate its involvement in cancer progres-
sion and metastasis.
8. Lgr5
Leucine-rich repeat-containing G-protein coupled receptor 5 or Gpr49 is a 
receptor formed by eight main domains [69]. Lgr5 was identified on the cellular 
surface of intestinal and colonic stem cells and is being considered thus a biomarker 
of them [70]. Lgr5 overexpression was also confirmed in esophageal and colon 
cancer, in hepatocellular carcinoma, and in ovarian cancer [70].
Lgr5 is expressed in both normal and tumor colonic tissues [69]. In normal 
colon tissue, Lgr5 is expressed in a small area of the intestinal crypts. Its expression 
area increases with cell transformation in adenoma and is most elevated in colon 
adenocarcinoma [69]. The percentage of colon cancer patients expressing Lgr5 is, 
according to literature studies, around 80% [70, 71].
Overexpression of Lgr5 in colon cancer correlates with advanced stages of the 
disease [70, 71], with lymph node involvement (L) [70, 71] and perineural invasion [71] 
and distant metastases (M) [70]. Lgr5 involvement in cellular proliferation is also sug-
gested due to the correlation found between Lgr5 expression and Ki-67 expression [70].
Lgr5 is thus considered to have a role in colon cancer development and progression and 
possibly in liver metastases formation as well [69]. Moreover, Lgr5 is considered to have a 
clinical role in predicting advanced pathological stages of colon cancer tumors [72].
9. ALDH1
Aldehyde dehydrogenase 1 is a detoxifying enzyme involved in colon cancer 
proliferation [73]. Expressed in low percentage in normal colonic mucosa, ALDH1 
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was found to be overexpressed in colon adenocarcinoma [73, 74]. A number of 
75.5–76.5% of colon cancer cases express ALDH1 at tumoral level [73, 74].
ALDH1 expression is associated with colon cancer location [73], with advanced 
stages of the disease [75], with number of lymph nodes involved (N) [73, 75, 76], 
and with perivenous invasion (V) [73] but also with local tumor recurrence [75]. 
The association between ALDH1 expression and lymph node involvement was not 
seen by Zhou et al. [74].
Recently, ALDH1 expression was found to be involved in epithelial-mesenchy-
mal transition (EMT) and could play, thus, a role in cancer progression and distant 
metastases formation [75–77].
Moreover, ALDH1 associates with resistance to chemotherapy [75] and poor 
overall survival [75, 76, 78].
In conclusion, ALDH1 could represent a promising prognostic marker in colon 
cancer patients that associate with advanced colon cancer stages and worse overall 
prognosis.
10. Conclusions
Colon cancer stem cells (CCSCs) could be responsible for tumor metastases, 
resistance to chemotherapy, and recurrence, and their identification is thus of major 
importance. However, the amount of biomarkers identified at the cellular surface of 
CCSC failed to become valuable prognostic markers, and further studies are neces-
sary to evaluate their role in cancer progression and distant metastases formation.
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Abstract
Living donation is still needed to overcome organ shortage. All countries seem 
to increase and encourage such kind of donation according to medical and ethi-
cal guidelines. The results of renal transplantation from living donors are better 
compared to those from cadaveric kidneys. Since the first successful kidney trans-
plantation from a living donor, some 63 years ago, surgery has shifted toward a less 
invasive approach offering to the donor less pain, better cosmesis, a shorter hospital 
stay, and a quick return to normal activities. Laparoscopic living-donor nephrec-
tomy (LLDN) is now considered as the gold standard approach for kidney retrieval 
on live donors and has undoubtedly revolutionized kidney donation. It must offer 
to the donor safety, low morbidity, and fast recovery and must obtain a graft with 
adequate vessel length, short warm ischemia time, and well-preserved ureteral 
blood supply. We describe our technique of LLDN according to safety principles 
and reproducible steps. Highly qualified and well-trained surgeons are allowed to 
perform such techniques within a very well-equipped environment and with expe-
rienced surgical staff. A living donor program should undertake at least 30 cases per 
year to maintain adequate experience and offer less complication rate.
Keywords: live donor, laparoscopy, nephrectomy, kidney transplantation,  
living kidney donation
1. Introduction
Living kidney donation has successfully improved the lives of many patients 
worldwide for over half a century. Do we still have the same need for living donors 
in 2018? The answer is obviously yes and for many reasons. The first is organ 
shortage with a widening gap between renal supply and demand in all countries 
that increases every year despite the use of marginal deceased donors. Waiting 
lists are growing everywhere. The site of the US Government Information on 
Organ Donation and Transplantation, organdonor.gov, shows recently a transplant 
waiting list of more than 114,000 patients of whom 83% are potential kidney 
recipients [1]. The second reason is the significant graft survival advantage and 
the reduction of the waiting time between end-stage renal disease and graft 
implantation. The results of renal transplantation from living donors are  better 
compared to those from cadaveric kidneys with a graft half-life of 18 versus 
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1. Introduction
Living kidney donation has successfully improved the lives of many patients 
worldwide for over half a century. Do we still have the same need for living donors 
in 2018? The answer is obviously yes and for many reasons. The first is organ 
shortage with a widening gap between renal supply and demand in all countries 
that increases every year despite the use of marginal deceased donors. Waiting 
lists are growing everywhere. The site of the US Government Information on 
Organ Donation and Transplantation, organdonor.gov, shows recently a transplant 
waiting list of more than 114,000 patients of whom 83% are potential kidney 
recipients [1]. The second reason is the significant graft survival advantage and 
the reduction of the waiting time between end-stage renal disease and graft 
implantation. The results of renal transplantation from living donors are  better 
compared to those from cadaveric kidneys with a graft half-life of 18 versus 
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12 years, respectively [2]. Kidney transplantation from a living donor, when 
possible, is the best treatment for most patients with end-stage renal disease. 
This is related to multiple factors such as less time from dialysis to transplanta-
tion, shorter cold ischemia time, and better quality of the graft. The third reason 
stands for pediatric recipients where a prompt transplantation from a living donor, 
mostly a parent, can help for a better growth, quick return to school, and a good 
psychological stability; it is considered today as the gold standard therapy for 
children with end-stage renal disease. The fourth argument is that living donation 
provides a good opportunity to perform a preemptive transplantation avoiding the 
need of going through dialysis. A fifth reason is that we are still too far to over-
come organ shortage by using xenografts from transgenic animals, or engineered 
organs from stem cells.
Currently, 40% of kidney grafts in the United States are from living donors [1]. 
In Europe, the level is highly variable between countries, standing for approxi-
mately 10% in France and up to 60% in Norway and Sweden [2, 3]. Approximately, 
one in three kidney transplants performed in the UK are from living donors [4], and 
according to the Global Observatory on Donation and Transplantation (GODT), 
84,347 kidney transplants were done worldwide in 2015, of which 41.8% were from 
living donors [5].
In some countries, namely Middle Eastern and Eastern, kidney transplantation 
is relying only or mostly on living donors [6, 7]. Worldwide kidney transplant from 
living donors in 2017, based on the International Registry in Organ Donation and 
Transplantation, is shown in Figure 1 [8].
Women traditionally outrank men in their enthusiasm to donate one of their 
kidneys. Although most recipients are male, women represented 63% of all living 
donations in 2016 [9].
In regard to these facts, living donors have exceptional courage and nobility; 
they go through a major surgery, accepting all surgical and medical risks and of no 
medical and physical benefit for them. It is our vocation and duty to provide them 
a safe and good practice according to legal and ethical bylaws and to protect their 
health in the long term.
2. Historical milestones
The first true altruistic voluntary living donation happened in Paris at Necker 
Hospital on December 25, 1952, when a mother, Gilberte Renard, convinced the 
medical team to give her kidney to her son Marius, 16 years old, apprentice car-
penter who had his right solitary kidney removed after falling from a scaffolding. 
Unfortunately, the graft remained functional for approximately 3 weeks despite the 
Figure 1. 
Worldwide kidney transplant from living donors in 2017. International Registry in Organ Donation and 
Transplantation.
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use of steroids and Marius died on January 27, 1953. His donating mother died in 
1992 at age 85 [10, 11].
The second important milestone happened 1 year later on December 23,1954 at 
Brigham Hospital in Boston USA, when Dr. Murray performed a successful renal 
transplantation on Richard Hersick, the donor being his monozygotic identical twin 
brother Ronald. The kidney was removed from Ronald by the urologist Harrison. 
No effort was made to preserve the isograft; but nonetheless, it functioned 
promptly despite 82 min of warm ischemia [12]. The graft remained functional for 
8 years and was lost due to a recurrence of the renal disease and causing the death 
of Richard. His brother Ronald died in 2010 at age 79, after a cardiac surgery, just 
4 days after the 56th anniversary of his pioneering kidney operation [11, 13].
The next two following years, the Brigham team performed seven successful 
kidney transplants also between identical twins. The most famous was that of Edith 
Helm, the third case at Brigham, who got pregnant 2 years after her transplant and 
was the first kidney recipient to carry to term and give birth to a child. Edith Helm 
also holds the record of the best graft longevity of 55 years; she died in 2011 at age 
76, with a functioning graft. Her donating identical twin sister, Wanda Foster, gave 
birth three times following her kidney donation and was still alive in 2016 [11, 14].
In 1960, the first kidney transplantation between genetically nonrelated 
patients was performed using immunosuppression. Late in 1963, a conference near 
Washington DC was held to present the overall findings from 216 recipients of renal 
allografts. The results were not gratifying: 52% of all those receiving grafts from 
related donors had died, and 81% of those with kidneys from unrelated or cadaveric 
donors. Joseph Murray concluded at that time that “kidney transplantation is still 
highly experimental and not yet a therapeutic procedure.” By 1965, 1 year survival 
rates of allografted kidneys from living related donors were much better approach-
ing 80%, due to better immunosuppression [12, 15].
In 1987, Alexandre et al. in Belgium published a first series of ABO-incompatible 
(ABO-I) living donors using splenectomy and heavy immunosuppressive regimen 
in the recipient. Results were fairly optimal [16].
Then, since 1989 and due to organ shortage, most ABO-I kidney transplanta-
tions have taken place in Japan with recently published data showing an excellent 
long-term outcome. Currently, ABO-I reached approximately 30% of all living 
donor renal transplantation in Japan [17, 18].
From the surgical point of view, all donor nephrectomies were done by open 
techniques mostly using a lumbar retroperitoneal approach; and the first successful 
trial of removing a live donor kidney using a laparoscopic approach was in 1995 at 
John’s Hopkins hospital by Ratner et al. [19]. Since then, considerable numbers of 
transplant centers worldwide have adopted laparoscopic donor nephrectomy (LDN) 
which is now considered as the gold standard approach for kidney retrieval on live 
donors and has undoubtedly revolutionized kidney donation.
3. Living donor evaluation
Suitability of the potential kidney recipient for transplantation must be estab-
lished before starting donor assessment. There is a significant variability among 
transplant programs in the criteria used to evaluate donors. ABO blood grouping is 
an important early screening test. Initial assessment of donor and recipient histo-
compatibility status must be undertaken at an early stage in living donor kidney 
transplant workup to avoid unnecessary and invasive clinical investigation [4]. 
Although donors are not true patients, they must undergo a complete and extensive 
evaluation before considering kidney removal. This evaluation includes medical and 
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12 years, respectively [2]. Kidney transplantation from a living donor, when 
possible, is the best treatment for most patients with end-stage renal disease. 
This is related to multiple factors such as less time from dialysis to transplanta-
tion, shorter cold ischemia time, and better quality of the graft. The third reason 
stands for pediatric recipients where a prompt transplantation from a living donor, 
mostly a parent, can help for a better growth, quick return to school, and a good 
psychological stability; it is considered today as the gold standard therapy for 
children with end-stage renal disease. The fourth argument is that living donation 
provides a good opportunity to perform a preemptive transplantation avoiding the 
need of going through dialysis. A fifth reason is that we are still too far to over-
come organ shortage by using xenografts from transgenic animals, or engineered 
organs from stem cells.
Currently, 40% of kidney grafts in the United States are from living donors [1]. 
In Europe, the level is highly variable between countries, standing for approxi-
mately 10% in France and up to 60% in Norway and Sweden [2, 3]. Approximately, 
one in three kidney transplants performed in the UK are from living donors [4], and 
according to the Global Observatory on Donation and Transplantation (GODT), 
84,347 kidney transplants were done worldwide in 2015, of which 41.8% were from 
living donors [5].
In some countries, namely Middle Eastern and Eastern, kidney transplantation 
is relying only or mostly on living donors [6, 7]. Worldwide kidney transplant from 
living donors in 2017, based on the International Registry in Organ Donation and 
Transplantation, is shown in Figure 1 [8].
Women traditionally outrank men in their enthusiasm to donate one of their 
kidneys. Although most recipients are male, women represented 63% of all living 
donations in 2016 [9].
In regard to these facts, living donors have exceptional courage and nobility; 
they go through a major surgery, accepting all surgical and medical risks and of no 
medical and physical benefit for them. It is our vocation and duty to provide them 
a safe and good practice according to legal and ethical bylaws and to protect their 
health in the long term.
2. Historical milestones
The first true altruistic voluntary living donation happened in Paris at Necker 
Hospital on December 25, 1952, when a mother, Gilberte Renard, convinced the 
medical team to give her kidney to her son Marius, 16 years old, apprentice car-
penter who had his right solitary kidney removed after falling from a scaffolding. 
Unfortunately, the graft remained functional for approximately 3 weeks despite the 
Figure 1. 
Worldwide kidney transplant from living donors in 2017. International Registry in Organ Donation and 
Transplantation.
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use of steroids and Marius died on January 27, 1953. His donating mother died in 
1992 at age 85 [10, 11].
The second important milestone happened 1 year later on December 23,1954 at 
Brigham Hospital in Boston USA, when Dr. Murray performed a successful renal 
transplantation on Richard Hersick, the donor being his monozygotic identical twin 
brother Ronald. The kidney was removed from Ronald by the urologist Harrison. 
No effort was made to preserve the isograft; but nonetheless, it functioned 
promptly despite 82 min of warm ischemia [12]. The graft remained functional for 
8 years and was lost due to a recurrence of the renal disease and causing the death 
of Richard. His brother Ronald died in 2010 at age 79, after a cardiac surgery, just 
4 days after the 56th anniversary of his pioneering kidney operation [11, 13].
The next two following years, the Brigham team performed seven successful 
kidney transplants also between identical twins. The most famous was that of Edith 
Helm, the third case at Brigham, who got pregnant 2 years after her transplant and 
was the first kidney recipient to carry to term and give birth to a child. Edith Helm 
also holds the record of the best graft longevity of 55 years; she died in 2011 at age 
76, with a functioning graft. Her donating identical twin sister, Wanda Foster, gave 
birth three times following her kidney donation and was still alive in 2016 [11, 14].
In 1960, the first kidney transplantation between genetically nonrelated 
patients was performed using immunosuppression. Late in 1963, a conference near 
Washington DC was held to present the overall findings from 216 recipients of renal 
allografts. The results were not gratifying: 52% of all those receiving grafts from 
related donors had died, and 81% of those with kidneys from unrelated or cadaveric 
donors. Joseph Murray concluded at that time that “kidney transplantation is still 
highly experimental and not yet a therapeutic procedure.” By 1965, 1 year survival 
rates of allografted kidneys from living related donors were much better approach-
ing 80%, due to better immunosuppression [12, 15].
In 1987, Alexandre et al. in Belgium published a first series of ABO-incompatible 
(ABO-I) living donors using splenectomy and heavy immunosuppressive regimen 
in the recipient. Results were fairly optimal [16].
Then, since 1989 and due to organ shortage, most ABO-I kidney transplanta-
tions have taken place in Japan with recently published data showing an excellent 
long-term outcome. Currently, ABO-I reached approximately 30% of all living 
donor renal transplantation in Japan [17, 18].
From the surgical point of view, all donor nephrectomies were done by open 
techniques mostly using a lumbar retroperitoneal approach; and the first successful 
trial of removing a live donor kidney using a laparoscopic approach was in 1995 at 
John’s Hopkins hospital by Ratner et al. [19]. Since then, considerable numbers of 
transplant centers worldwide have adopted laparoscopic donor nephrectomy (LDN) 
which is now considered as the gold standard approach for kidney retrieval on live 
donors and has undoubtedly revolutionized kidney donation.
3. Living donor evaluation
Suitability of the potential kidney recipient for transplantation must be estab-
lished before starting donor assessment. There is a significant variability among 
transplant programs in the criteria used to evaluate donors. ABO blood grouping is 
an important early screening test. Initial assessment of donor and recipient histo-
compatibility status must be undertaken at an early stage in living donor kidney 
transplant workup to avoid unnecessary and invasive clinical investigation [4]. 
Although donors are not true patients, they must undergo a complete and extensive 
evaluation before considering kidney removal. This evaluation includes medical and 
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surgical past history, risk factors like alcohol intake and smoking, family history 
(mainly renal disease, hypertension, and diabetes), renal, liver, and cardiopulmo-
nary function. They should have no active malignancy or infection. The waiting 
period before transplant in recipients with a history of malignancy depends on the 
type, TNM stage and grade of the tumor, and recipient’s age and general health. 
Recipients with tumors that have a low recurrence rate can be considered for imme-
diate transplantation after successful treatment. Active HBV and HCV are usually 
contraindications to living donor kidney donation; and HIV infection is an absolute 
contraindication. Screening of serum prostate-specific antigen (PSA) is mandatory 
in males above 54 years as also mammograms in women. A urine albumin/creatinine 
ratio done on a spot urine sample is a recommended screening test and it should be 
<30 mg/mmol. The presence of persistent microhematuria (two or more positive 
urine analysis) or recently called “persistent nonvisible hematuria,” with no evident 
explanation like stones, neoplasms, and infection, should be investigated with cys-
toscopy and renal biopsy. Assessment of renal function is based on serum creatinine 
and calculation of creatinine clearance. Differential kidney function, using DMSA 
isotope scanning, is recommended when there is >10% variation in kidney size or 
abnormal renal anatomy [4]. Donors with mild and well-controlled hypertension, 
on one or two antihypertensive drugs, and with no evidence of end organ damage 
(retinopathy, left ventricular hypertrophy, proteinuria), might be accepted [20]. 
Data regarding long-term safety of nephrectomy in hypertensive donors are modest; 
but small studies with short-term follow-up suggest no increase in the incidence of 
kidney disease or worsening of the control of hypertension in donors with a his-
tory of mild well-controlled hypertension [21]. The Amsterdam Forum consensus 
guidelines in 2004 stated that some patients (age > 50, GFR >80, and with low urine 
albumin excretion of <30 mg/d) with easily controlled hypertension can represent 
a low-risk group for the development of kidney disease but might be considered 
as donors [22]. A psychosocial assessment is recommended for all donors with 
appropriate referral to a mental health professional who can be a psychologist or a 
psychiatrist. This assessment also evaluates whether the decision to donate is free of 
constraint and other undue pressures. Donor age is suggested to be between 22 and 
75 years; but the upper age limit can be beyond if the donor is in good health and 
with a normal range of age-related change in kidney function (e.g., advisory thresh-
old GFR levels considered acceptable at age 80 years is 58 ml/min/1.73 m2 for males 
and 49 ml/min/1.73 m2 for females). A safe threshold level of predonation kidney 
function is one that leaves sufficient function after donation to maintain the donor 
in normal status without affecting lifespan [4]. Old donors (> 60 years) should be 
aware of a greater risk of pre- and postoperative complications. We are very cautious 
about young donors who are less than 30 years old because their absolute risk over 
a lifetime, particularly with additional risk factors for end-stage renal disease (like 
hypertension, obesity, and diabetes), is likely to be more significant [4]. Living 
donors should ideally have a body mass index (BMI) that is less than 30 kg/m2. Data 
on the safety of kidney donation in the very obese (BMI >35 kg/m2) are limited and 
donation should be discouraged. Morbid obesity increases the risk of hypertension, 
dyslipidemia, insulin resistance and diabetes, heart disease, stroke, sleep apnea, and 
certain cancers [23]. On the other hand, data suggest that laparoscopic living-donor 
nephrectomy (LLDN) is an increasingly safe procedure in the otherwise healthy 
obese kidney donor and does not result in a high rate of major perioperative compli-
cations [24, 25]. Also, transplantation from an old or obese donor is most probably 
better than dialysis or transplantation from a deceased donor [26]. Computed 
tomography and tomographic angiography are used to assess renal vascular anatomy 
(presence of accessory vessels, intervessel distance, distance from ostium to the 
first division, presence of atherosclerotic disease), renal dimensions, presence of 
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stones, urinary tract anatomy, and the existence of any suspicious lesion not seen 
on ultrasound. Around 25% of will have multiple arteries to one kidney and 7% 
will have multiple vessels to both kidneys [27]. Renal pedicles with less than three 
arteries are accepted.
The presence of multiple renal cystic lesions in a potential living kidney donor 
requires careful evaluation and a detailed family history; in those with a family his-
tory of polycystic kidney disease under the age of 40 years, the presence of two or 
more cysts (unilateral or bilateral) indicates autosomal dominant polycystic disease 
(ADPKD) and exclude donation [28]. For those aged 40–59 years, the absence of at 
least two cysts in each kidney gives a 100% negative predictive value for ADPKD, 
while for those older, up to four cysts are acceptable in each kidney [4]. History or 
current presence of bilateral renal stones is a contra indication for donation; but in 
some centers, donors with a history of nephrolithiasis are accepted as long as stones 
are no longer present and metabolic studies are normal [29].
4. Surgical technique
Multiple techniques have been described to harvest a kidney from a living donor. 
The old classic open surgery performed through a lumbar or subcostal incision is 
nowadays much less popular compared to mini-invasive approaches using laparo-
scopic extra corporeal manipulation and magnified ultrahigh definition view of the 
surgical field. But regardless of how minimally invasive laparoscopy can be, living 
donor nephrectomy remains a maximally invasive surgery because we are dealing 
with major vessels and consequently very serious and sometimes lethal hemorrhagic 
complications might occur. Highly qualified, competent, and well-trained surgeons 
are allowed to perform such techniques within a very well-equipped environment 
and with experienced surgical staff. A living donor program should undertake at 
least 30 cases per year to maintain adequate experience. Today, laparoscopy is by far 
the preferred procedure for kidney removal in live donors, offering a quick recovery, 
less pain, and a shorter hospital stay; and it will be the technique detailed in this 
chapter. A well-informed consent is obtained prior to surgery. The surgeon perform-
ing living donor nephrectomy has a particular responsibility to ensure that the donor 
fully understands the potential risks and long-term effects of the operation. Surgery 
must offer to the donor safety, low morbidity, and fast recovery; and must obtain 
a graft with adequate vessel length, short warm ischemia time, and well-preserved 
ureteral blood supply. A donor kidney with a single renal artery should, whenever 
possible, be chosen for transplantation to minimize the risk of vascular complica-
tions in the recipient procedure; similarly, single renal veins are usually preferred. 
Many transplant centers prefer the left kidney for LLDN because of the longer vein 
and perhaps an easier surgery on the left side; but with increasing experience, kid-
ney side was not a real obstacle [30] although for some authors the right kidney was 
the only risk factor for early graft thrombosis [31, 32]. The answer to which kidney 
to take when facing a donor with two arteries on the left and a single artery on the 
right is based on the surgeon’s experience of laparoscopic right nephrectomy and his 
skills in reconstructing the vasculature of the graft. The presence of a retroaortic 
renal vein is of no problem with no increased complications; and it is even an easier 
case because of the large distance between the artery and the retroaortic vein which 
is in an inferior position (Figure 2). The most important criterion regarding the side 
to be chosen for retrieval is to keep the better kidney for the living donor.
There is variability among different centers on the choice of laparoscopic tech-
nique between only pure laparoscopy (transperitoneal versus retroperitoneal), only 
hand-assisted laparoscopy or a combination of both. Laparoendoscopic single-site 
Basic Principles and Practice in Surgery
26
surgical past history, risk factors like alcohol intake and smoking, family history 
(mainly renal disease, hypertension, and diabetes), renal, liver, and cardiopulmo-
nary function. They should have no active malignancy or infection. The waiting 
period before transplant in recipients with a history of malignancy depends on the 
type, TNM stage and grade of the tumor, and recipient’s age and general health. 
Recipients with tumors that have a low recurrence rate can be considered for imme-
diate transplantation after successful treatment. Active HBV and HCV are usually 
contraindications to living donor kidney donation; and HIV infection is an absolute 
contraindication. Screening of serum prostate-specific antigen (PSA) is mandatory 
in males above 54 years as also mammograms in women. A urine albumin/creatinine 
ratio done on a spot urine sample is a recommended screening test and it should be 
<30 mg/mmol. The presence of persistent microhematuria (two or more positive 
urine analysis) or recently called “persistent nonvisible hematuria,” with no evident 
explanation like stones, neoplasms, and infection, should be investigated with cys-
toscopy and renal biopsy. Assessment of renal function is based on serum creatinine 
and calculation of creatinine clearance. Differential kidney function, using DMSA 
isotope scanning, is recommended when there is >10% variation in kidney size or 
abnormal renal anatomy [4]. Donors with mild and well-controlled hypertension, 
on one or two antihypertensive drugs, and with no evidence of end organ damage 
(retinopathy, left ventricular hypertrophy, proteinuria), might be accepted [20]. 
Data regarding long-term safety of nephrectomy in hypertensive donors are modest; 
but small studies with short-term follow-up suggest no increase in the incidence of 
kidney disease or worsening of the control of hypertension in donors with a his-
tory of mild well-controlled hypertension [21]. The Amsterdam Forum consensus 
guidelines in 2004 stated that some patients (age > 50, GFR >80, and with low urine 
albumin excretion of <30 mg/d) with easily controlled hypertension can represent 
a low-risk group for the development of kidney disease but might be considered 
as donors [22]. A psychosocial assessment is recommended for all donors with 
appropriate referral to a mental health professional who can be a psychologist or a 
psychiatrist. This assessment also evaluates whether the decision to donate is free of 
constraint and other undue pressures. Donor age is suggested to be between 22 and 
75 years; but the upper age limit can be beyond if the donor is in good health and 
with a normal range of age-related change in kidney function (e.g., advisory thresh-
old GFR levels considered acceptable at age 80 years is 58 ml/min/1.73 m2 for males 
and 49 ml/min/1.73 m2 for females). A safe threshold level of predonation kidney 
function is one that leaves sufficient function after donation to maintain the donor 
in normal status without affecting lifespan [4]. Old donors (> 60 years) should be 
aware of a greater risk of pre- and postoperative complications. We are very cautious 
about young donors who are less than 30 years old because their absolute risk over 
a lifetime, particularly with additional risk factors for end-stage renal disease (like 
hypertension, obesity, and diabetes), is likely to be more significant [4]. Living 
donors should ideally have a body mass index (BMI) that is less than 30 kg/m2. Data 
on the safety of kidney donation in the very obese (BMI >35 kg/m2) are limited and 
donation should be discouraged. Morbid obesity increases the risk of hypertension, 
dyslipidemia, insulin resistance and diabetes, heart disease, stroke, sleep apnea, and 
certain cancers [23]. On the other hand, data suggest that laparoscopic living-donor 
nephrectomy (LLDN) is an increasingly safe procedure in the otherwise healthy 
obese kidney donor and does not result in a high rate of major perioperative compli-
cations [24, 25]. Also, transplantation from an old or obese donor is most probably 
better than dialysis or transplantation from a deceased donor [26]. Computed 
tomography and tomographic angiography are used to assess renal vascular anatomy 
(presence of accessory vessels, intervessel distance, distance from ostium to the 
first division, presence of atherosclerotic disease), renal dimensions, presence of 
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stones, urinary tract anatomy, and the existence of any suspicious lesion not seen 
on ultrasound. Around 25% of will have multiple arteries to one kidney and 7% 
will have multiple vessels to both kidneys [27]. Renal pedicles with less than three 
arteries are accepted.
The presence of multiple renal cystic lesions in a potential living kidney donor 
requires careful evaluation and a detailed family history; in those with a family his-
tory of polycystic kidney disease under the age of 40 years, the presence of two or 
more cysts (unilateral or bilateral) indicates autosomal dominant polycystic disease 
(ADPKD) and exclude donation [28]. For those aged 40–59 years, the absence of at 
least two cysts in each kidney gives a 100% negative predictive value for ADPKD, 
while for those older, up to four cysts are acceptable in each kidney [4]. History or 
current presence of bilateral renal stones is a contra indication for donation; but in 
some centers, donors with a history of nephrolithiasis are accepted as long as stones 
are no longer present and metabolic studies are normal [29].
4. Surgical technique
Multiple techniques have been described to harvest a kidney from a living donor. 
The old classic open surgery performed through a lumbar or subcostal incision is 
nowadays much less popular compared to mini-invasive approaches using laparo-
scopic extra corporeal manipulation and magnified ultrahigh definition view of the 
surgical field. But regardless of how minimally invasive laparoscopy can be, living 
donor nephrectomy remains a maximally invasive surgery because we are dealing 
with major vessels and consequently very serious and sometimes lethal hemorrhagic 
complications might occur. Highly qualified, competent, and well-trained surgeons 
are allowed to perform such techniques within a very well-equipped environment 
and with experienced surgical staff. A living donor program should undertake at 
least 30 cases per year to maintain adequate experience. Today, laparoscopy is by far 
the preferred procedure for kidney removal in live donors, offering a quick recovery, 
less pain, and a shorter hospital stay; and it will be the technique detailed in this 
chapter. A well-informed consent is obtained prior to surgery. The surgeon perform-
ing living donor nephrectomy has a particular responsibility to ensure that the donor 
fully understands the potential risks and long-term effects of the operation. Surgery 
must offer to the donor safety, low morbidity, and fast recovery; and must obtain 
a graft with adequate vessel length, short warm ischemia time, and well-preserved 
ureteral blood supply. A donor kidney with a single renal artery should, whenever 
possible, be chosen for transplantation to minimize the risk of vascular complica-
tions in the recipient procedure; similarly, single renal veins are usually preferred. 
Many transplant centers prefer the left kidney for LLDN because of the longer vein 
and perhaps an easier surgery on the left side; but with increasing experience, kid-
ney side was not a real obstacle [30] although for some authors the right kidney was 
the only risk factor for early graft thrombosis [31, 32]. The answer to which kidney 
to take when facing a donor with two arteries on the left and a single artery on the 
right is based on the surgeon’s experience of laparoscopic right nephrectomy and his 
skills in reconstructing the vasculature of the graft. The presence of a retroaortic 
renal vein is of no problem with no increased complications; and it is even an easier 
case because of the large distance between the artery and the retroaortic vein which 
is in an inferior position (Figure 2). The most important criterion regarding the side 
to be chosen for retrieval is to keep the better kidney for the living donor.
There is variability among different centers on the choice of laparoscopic tech-
nique between only pure laparoscopy (transperitoneal versus retroperitoneal), only 
hand-assisted laparoscopy or a combination of both. Laparoendoscopic single-site 
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surgery (LESS), natural orifice transluminal endoscopic surgery (NOTES), and 
robotic-assisted are other interesting techniques that still need to be evaluated. 
In our experience, we started our first 10 cases with hand assistance, given the 
increased security that it provides, and then switched to pure transperitoneal 
laparoscopic approach which will be detailed in this chapter.
4.1 Anesthesia
Laparoscopic donor nephrectomy has had a big impact on anesthesia and 
recovery of this special category of patients. Intraoperative anesthesia for lapa-
roscopic live donors follows the rules of laparoscopic kidney surgery as far as 
sedation and muscle relaxation but the concept of protection of the donor kidney 
is mandatory throughout the case, one among many disparities compared to other 
kidney surgeries [33]. Nowadays, two large-bore IV catheters are considered more 
than enough as far as vascular access and risk of bleeding. Arterial lines are not 
recommended and noninvasive blood pressure monitoring is a reasonable option 
[34]. After induction of anesthesia, classically with propofol and a neuromuscular 
blocking agent, maintenance of anesthesia has been the subject of many studies 
to evaluate the nephrotoxicity of various agents. While isoflurane and desflurane 
were considered safe and with the least toxicity on the kidney, this was not the 
case with sevoflurane that is associated with production of compound A in the 
circulation; a direct nephrotoxic substance [35]. Despite many works, the type of 
anesthetic agent was not shown to impact serum creatinine or GFR in transplanted 
grafts and it was concluded that toxicity, if any, was minimal. Nitrous oxide is one 
agent preferably avoided in laparoscopic surgery as it can cause bowel distention 
in more than 50% of cases and subsequent compromise of insufflation or surgical 
field exposure in near 25% of laparoscopic donor nephrectomy, increasing the need 
even more for neuromuscular blocking agents [36]. Mechanical ventilation set-
tings are not different from other laparoscopic procedures. Special considerations 
for donor nephrectomy would include tolerance of mild hypercapnia to 45 mmHg 
since it helps better tissue perfusion and circulation in light of pneumoperitoneum. 
Positive-end expiratory pressure (PEEP) at 5–10 mmHg, a 20–30% increase in 
minute ventilation reflecting an increased respiratory rate with constant volumes, 
is similar to other laparoscopic procedures. The effects of pneumoperitoneum were 
explored by studies on rats demonstrating that abdominal insufflation with CO2 
during laparoscopy in subjects with chronic renal function impairment should not 
be a contraindication to surgery [37]. Additionally, if insufflation had a substantial 
negative effect on kidney function, we would have expected this to have a great 
impact on kidney donors out of concern on the retained kidney, which has not been 
Figure 2. 
Retroaortic vein (V). See the distance between the artery (A) and the vein (V). U = ureter.
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born out in the literature. IV hydration holds a crucial place in counteracting the 
notorious effects of pneumoperitoneum on tissue perfusion and renal plasma flow 
caused by an increased intraperitoneal pressure sometimes near 15 mmHg. Some 
studies emphasized the great effects of hydration on mean arterial pressure preser-
vation and ensuring hemodynamic stability [38]. Whether this is realized by giving 
donors colloid boluses preoperatively or during surgery is based on institutional 
protocols and the team preferences. In general, a patient undergoing laparoscopic 
donor nephrectomy should get 4–6 L during the procedure to maintain at least a 
urine output >50 mL/h [38]. This will help avoid the use of any vasopressors or 
inotrope agents because of the associated deleterious renal vasoconstriction. If 
they become really needed, ephedrine is the best agent to start with, giving small 
boluses in order to attain the desired effects. IV fluids should be warmed and full 
measures should be taken to prevent hypothermia. There is a mounting evidence 
to suggest that 0.9% normal saline can be detrimental to patient outcome, and may 
indeed contribute to renal dysfunction, and therefore, the use of this solution in 
donors cannot be recommended; Ringer’s lactate solution is the intravenous fluid of 
choice [4]. The administration of mannitol 12–25 g once or twice, or furosemide at 
small doses during the case, is another example of common practice depending on 
departmental protocols, but they lack any definite data or evidence to support it.
4.2 Antibiotics, patient position, and trocar placement
We routinely give antibiotic prophylaxis based on one single shot of cefazolin. 
After placement of a Foley catheter, the patient is put in a complete lateral decubitus 
position almost 90° to the table without any flexure or kidney rest; the belly being 
on the external border of the table. Arms and legs are well secured with pillows 
and gel pads to prevent any vascular or nerve compression. We start by doing the 
extraction site as a small transverse supra pubic incision 6–8 cm width, depending 
on donor kidney size, with opening of the peritoneum and insertion of a LapCap 
device (Applied Medical-Alexis Laparoscopic System with Kii® Fios® First Entry) 
(Figure 3 and Video 1 (https://youtu.be/LBWXDCD2Upk)). Pneumoperitoneum 
induction is made through this device. Intraabdominal CO2 pressure is fixed at 
12 mm Hg. The use of low-pressure pneumoperitoneum with deep neuromuscular 
block did not seem to reduce postoperative pain scores or improve the overall qual-
ity of recovery after surgery [39]. After complete insufflation, we insert all trocars 
under direct vision. On the left side, the first is a 10 mm placed umbilical or para 
umbilical depending on obesity status; the second is a 5 mm placed subcostal on the 
level of the anterior axillary line, and the third one is a 12 mm trocar (which comes 
in the LapCap package) placed in the left iliac fossa (Figure 3). On the right side, 
Figure 3. 
Left side: position of patient and 3 trocar placement: 5 mm subcostal, 10 mm umbilical or para umbilical 
(yellow dot) depending on obesity, and 12 mm left iliac fossa. LapCap device shown on the right.
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surgery (LESS), natural orifice transluminal endoscopic surgery (NOTES), and 
robotic-assisted are other interesting techniques that still need to be evaluated. 
In our experience, we started our first 10 cases with hand assistance, given the 
increased security that it provides, and then switched to pure transperitoneal 
laparoscopic approach which will be detailed in this chapter.
4.1 Anesthesia
Laparoscopic donor nephrectomy has had a big impact on anesthesia and 
recovery of this special category of patients. Intraoperative anesthesia for lapa-
roscopic live donors follows the rules of laparoscopic kidney surgery as far as 
sedation and muscle relaxation but the concept of protection of the donor kidney 
is mandatory throughout the case, one among many disparities compared to other 
kidney surgeries [33]. Nowadays, two large-bore IV catheters are considered more 
than enough as far as vascular access and risk of bleeding. Arterial lines are not 
recommended and noninvasive blood pressure monitoring is a reasonable option 
[34]. After induction of anesthesia, classically with propofol and a neuromuscular 
blocking agent, maintenance of anesthesia has been the subject of many studies 
to evaluate the nephrotoxicity of various agents. While isoflurane and desflurane 
were considered safe and with the least toxicity on the kidney, this was not the 
case with sevoflurane that is associated with production of compound A in the 
circulation; a direct nephrotoxic substance [35]. Despite many works, the type of 
anesthetic agent was not shown to impact serum creatinine or GFR in transplanted 
grafts and it was concluded that toxicity, if any, was minimal. Nitrous oxide is one 
agent preferably avoided in laparoscopic surgery as it can cause bowel distention 
in more than 50% of cases and subsequent compromise of insufflation or surgical 
field exposure in near 25% of laparoscopic donor nephrectomy, increasing the need 
even more for neuromuscular blocking agents [36]. Mechanical ventilation set-
tings are not different from other laparoscopic procedures. Special considerations 
for donor nephrectomy would include tolerance of mild hypercapnia to 45 mmHg 
since it helps better tissue perfusion and circulation in light of pneumoperitoneum. 
Positive-end expiratory pressure (PEEP) at 5–10 mmHg, a 20–30% increase in 
minute ventilation reflecting an increased respiratory rate with constant volumes, 
is similar to other laparoscopic procedures. The effects of pneumoperitoneum were 
explored by studies on rats demonstrating that abdominal insufflation with CO2 
during laparoscopy in subjects with chronic renal function impairment should not 
be a contraindication to surgery [37]. Additionally, if insufflation had a substantial 
negative effect on kidney function, we would have expected this to have a great 
impact on kidney donors out of concern on the retained kidney, which has not been 
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born out in the literature. IV hydration holds a crucial place in counteracting the 
notorious effects of pneumoperitoneum on tissue perfusion and renal plasma flow 
caused by an increased intraperitoneal pressure sometimes near 15 mmHg. Some 
studies emphasized the great effects of hydration on mean arterial pressure preser-
vation and ensuring hemodynamic stability [38]. Whether this is realized by giving 
donors colloid boluses preoperatively or during surgery is based on institutional 
protocols and the team preferences. In general, a patient undergoing laparoscopic 
donor nephrectomy should get 4–6 L during the procedure to maintain at least a 
urine output >50 mL/h [38]. This will help avoid the use of any vasopressors or 
inotrope agents because of the associated deleterious renal vasoconstriction. If 
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and gel pads to prevent any vascular or nerve compression. We start by doing the 
extraction site as a small transverse supra pubic incision 6–8 cm width, depending 
on donor kidney size, with opening of the peritoneum and insertion of a LapCap 
device (Applied Medical-Alexis Laparoscopic System with Kii® Fios® First Entry) 
(Figure 3 and Video 1 (https://youtu.be/LBWXDCD2Upk)). Pneumoperitoneum 
induction is made through this device. Intraabdominal CO2 pressure is fixed at 
12 mm Hg. The use of low-pressure pneumoperitoneum with deep neuromuscular 
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ity of recovery after surgery [39]. After complete insufflation, we insert all trocars 
under direct vision. On the left side, the first is a 10 mm placed umbilical or para 
umbilical depending on obesity status; the second is a 5 mm placed subcostal on the 
level of the anterior axillary line, and the third one is a 12 mm trocar (which comes 
in the LapCap package) placed in the left iliac fossa (Figure 3). On the right side, 
Figure 3. 
Left side: position of patient and 3 trocar placement: 5 mm subcostal, 10 mm umbilical or para umbilical 
(yellow dot) depending on obesity, and 12 mm left iliac fossa. LapCap device shown on the right.
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trocar placement is the same with an additional 5 mm one, inserted at the xiphoid 
for liver retraction. Additional ports can be used in some rare difficult cases and 
sometimes we do percutaneous kidney suspension using a 2/0 silk on a straight 
needle through Gerota’s fascia and perirenal fat (Figure 4).
4.3 Surgical steps
As described in all transperitoneal approaches, we start by taking the colon off 
the kidney medially along the Toldt’s fascia from the iliac vessels up to the colonic 
angle (splenic flexure on the left and hepatic flexure on the right). Gerota’s fascia 
is left intact on the kidney (Figure 5). The lateral and parietal attachments of the 
kidney are left in place to prevent the kidney from slipping down and disturb-
ing later the hilar dissection. We use from the start a LigaSure™ Maryland 5 mm 
(Covidien) sealing device. We then dissect and isolate the ureter inferiorly down 
to the iliac vessels with identification of the psoas muscle and the genital vessels. 
All periureteral and inferior renal pole fat must be well preserved to keep a well-
vascularized ureter (Figure 6). Avoid any injury to the genitofemoral nerve and 
try to keep the psoas fascia in place. The gonadal vein can be divided proximally 
and distally and kept with the ureter in order to protect ureteric vascularity. This 
is thought to be the cause of postoperative ipsilateral orchialgia, which occurs in 
6.2–9.6% of male donors [40, 41]. Large studies, however, have demonstrated that 
leaving the gonadal vein in situ does not lead to increased ureteric complications in 
the transplant recipient [42] and prevents orchialgia [40, 43].
4.3.1 Left-sided nephrectomy
The ureter and its peri ureteral fat are lifted up to undertake an upper dissection 
along the genital vein until we reach the inferior border and the anterior aspect of the 
renal vein (Video 2 (https://youtu.be/Ms38M9mIV0Q)). Then, the spleen and tail of 
the pancreas are completely mobilized by cutting the splenorenal and splenophrenic 
ligaments (Video 3 (https://youtu.be/lKNHPx66Mgo)). Care is taken not to injure the 
pancreas, the splenic artery, and the stomach near the level of the crus of the dia-
phragm where dissection ends. By achieving this step, the space between the spleen and 
the kidney is usually widely opened and permits partial mobilization of the upper renal 
pole (Figure 7). We then proceed to adrenal dissection and separation starting very 
carefully from the upper border of the renal vein toward the upper pole of the kidney 
with division of the adrenal vein using LigaSure sealing without any clip placement and 
caring not to injure the anterior branch of the renal artery or small upper pole accessory 
Figure 4. 
Left kidney suspended with a 2/0 silk suture on the parietal wall.
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arteries not detected on the preoperative renal angio CT scan (Video 4 (https://youtu.
be/WbgzAzZZprk)). This step will almost complete the upper pole release.
The renal pedicle is now ready to be dissected. Before starting the hilar dissec-
tion, 12–25 mg of mannitol is administered. All lymphatics and autonomic nerve 
plexuses superior to the vein and around the renal artery are sealed and cut. Some 
small segments of these structures are sometimes difficult or possibly dangerous 
to access, and in such a case, they are quickly sealed and cut after the stapling of 
the renal pedicle. Very careful and minutious dissection is undertaken between 
the artery and vein to prepare a clear, precise, and secure positioning of the sta-
pling device. The left renal artery is dissected at its aortic origin (Video 5 (https://
youtu.be/5wyqkJz7ick)). If vasospasm is noted, the renal artery can be bathed in a 
papaverine solution (30 mg/ml) [44]. In some cases, retroperitoneal veins (lumbar, 
ascending lumbar, and hemiazygos) join the left renal vein in up to 75% of indi-
viduals, and it must be sealed and cut [45]. Clips are avoided on all venous branches 
Figure 5. 
Left renal aspect after colon dissection. Gerota’s fascia is left intact.
Figure 6. 
Ureter with well-preserved periureteral fat and vasculature.
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All periureteral and inferior renal pole fat must be well preserved to keep a well-
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try to keep the psoas fascia in place. The gonadal vein can be divided proximally 
and distally and kept with the ureter in order to protect ureteric vascularity. This 
is thought to be the cause of postoperative ipsilateral orchialgia, which occurs in 
6.2–9.6% of male donors [40, 41]. Large studies, however, have demonstrated that 
leaving the gonadal vein in situ does not lead to increased ureteric complications in 
the transplant recipient [42] and prevents orchialgia [40, 43].
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The ureter and its peri ureteral fat are lifted up to undertake an upper dissection 
along the genital vein until we reach the inferior border and the anterior aspect of the 
renal vein (Video 2 (https://youtu.be/Ms38M9mIV0Q)). Then, the spleen and tail of 
the pancreas are completely mobilized by cutting the splenorenal and splenophrenic 
ligaments (Video 3 (https://youtu.be/lKNHPx66Mgo)). Care is taken not to injure the 
pancreas, the splenic artery, and the stomach near the level of the crus of the dia-
phragm where dissection ends. By achieving this step, the space between the spleen and 
the kidney is usually widely opened and permits partial mobilization of the upper renal 
pole (Figure 7). We then proceed to adrenal dissection and separation starting very 
carefully from the upper border of the renal vein toward the upper pole of the kidney 
with division of the adrenal vein using LigaSure sealing without any clip placement and 
caring not to injure the anterior branch of the renal artery or small upper pole accessory 
Figure 4. 
Left kidney suspended with a 2/0 silk suture on the parietal wall.
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arteries not detected on the preoperative renal angio CT scan (Video 4 (https://youtu.
be/WbgzAzZZprk)). This step will almost complete the upper pole release.
The renal pedicle is now ready to be dissected. Before starting the hilar dissec-
tion, 12–25 mg of mannitol is administered. All lymphatics and autonomic nerve 
plexuses superior to the vein and around the renal artery are sealed and cut. Some 
small segments of these structures are sometimes difficult or possibly dangerous 
to access, and in such a case, they are quickly sealed and cut after the stapling of 
the renal pedicle. Very careful and minutious dissection is undertaken between 
the artery and vein to prepare a clear, precise, and secure positioning of the sta-
pling device. The left renal artery is dissected at its aortic origin (Video 5 (https://
youtu.be/5wyqkJz7ick)). If vasospasm is noted, the renal artery can be bathed in a 
papaverine solution (30 mg/ml) [44]. In some cases, retroperitoneal veins (lumbar, 
ascending lumbar, and hemiazygos) join the left renal vein in up to 75% of indi-
viduals, and it must be sealed and cut [45]. Clips are avoided on all venous branches 
Figure 5. 
Left renal aspect after colon dissection. Gerota’s fascia is left intact.
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Ureter with well-preserved periureteral fat and vasculature.
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to prevent their later insertion between the jaws of the stapling device leading to 
misfire and serious malfunction [46].
The ureter and its periureteral fat are again lifted up at the level of the iliac 
vessels and posterior dissection will start from here and go up to the whole posterior 
surface of the kidney. The ureter is isolated with a generous periureteric fat. After 
completing this posterior release, the kidney is completely lying medially and we 
can free the posterior aspect of the renal artery (Figure 8; Video 6 (https://youtu.
be/xQswiMds4Nc)). Now the kidney is supposed to hold only on the artery, vein, 
and ureter and is ready to be harvested. The patient is given another dose of man-
nitol. An Endocatch bag 15 mm (Covidien) is inserted through the LapCap. The 
distal ureter is clipped and sectioned. A good flow of urine should be noticed before 
pedicle clamping. A number of vascular transfixing stapling devices are available 
for surgeons to secure the renal vessels. The choice of which device to use is down to 
surgeon preference. Recently, we rely on two stapling devices: Endo-TA 30 stapler 
(30-mm length, 2.5-mm staples-Covidien) if maximum length is needed because 
this device delivers three rows of staplers without a cutting knife and no articula-
tion; and vessels are cut with cold scissors; and Echelon Flex™ Powered Vascular 
Stapler 35 mm (Ethicon) with manual articulation for more precise placement, a 
narrow curved blunt tip, and reduction in tip movement during firing; this device 
delivers four rows of staples (instead of six) in a staggered pattern and gives a very 
secure vascular control and less loss in vessel length with nonbloody surgical field 
because of the absent backflow. Stapling starts on the renal artery and then quickly 
on the vein, and the kidney is rapidly placed in the Endo bag and extracted through 
the LapCap (Videos 7 (https://youtu.be/RfIGOjtqpD8) and 8 (https://youtu.be/
dGUKd3R23Yo)). We do not give intravenous heparin prior to vascular occlusion. 
Figure 7. 
Spleen separated from the left renal upper pole.
Figure 8. 
Laparoscopic view after posterior left renal dissection.
33
Laparoscopic Live Donor Nephrectomy: Techniques and Results
DOI: http://dx.doi.org/10.5772/intechopen.80880
Warm ischemia time is usually around 3–5 min before the kidney is flushed out on 
ice with the preservation solution.
Originally, the artery was secured using locking polymer clips that are much 
cheaper than staples. On April 2006, the manufacturer of Weck Hem-o-lok ligating 
clips, Teleflex Medical, added a contraindication to the use of these clips on renal vessels 
in laparoscopic live donor nephrectomy, after receiving 15 medical device reports of 
12 injuries and 3 deaths, all of which occurred between November 19, 2001 and March 
20, 2005. All reports were associated with using the clips for ligation of the renal artery 
during LLDN [47, 48]. Clip dislodgement may occur several hours following the proce-
dure resulting in fatal hemorrhage on the ward [49]. US Food and Drug Administration 
(FDA) issued on May 2011 a warning to healthcare providers that Weck Hem-o-Lok 
ligating clips should not be used for the ligation of the renal artery during LLDN 
because of serious risks and potential life-threatening complications to the donor [50]. 
On the other hand, surgeons must be aware that reported failure rates for staplers are 
3.0% [51]. Stapler misfire rates can be reduced by avoiding the use of titanium and 
other clips around the hilar structures before securing the renal pedicle [46].
Before ending the surgery, latero aortic and inter aorto caval lymphatics are 
clipped (Hem-o-lok clips) to prevent chylous leakage (Video 9 (https://youtu.be/_
c4rjTtvlTw)). Meticulous and extensive clipping remains the safest way of securing 
lymphatic channels along the dissection area despite being usually burned with 
energy-based sealing devices. It has been shown that bipolar cautery can effectively 
ligate and control lymph leakage as also other laparoscopic dissection devices using 
bipolar and ultrasonic energy but monopolar scissors were unreliable with respect 
to sealing lymphatic channels [52, 53]. Last view of the whole surgical field is done 
with particular inspection of the vascular stumps (Figure 9). Pneumoperitoneum is 
exsufflated. No drainage is usually needed. Port and extraction sites are closed.
4.3.2 Right-sided nephrectomy
In some patients, the right side seems to be easier than the left. Steps are almost 
the same. Trocar placement has the same distribution as on the left except for an 
additional 5 mm trocar inserted at the xiphoid for liver retraction (Figure 10). Less 
right colon dissection is needed and careful duodenal displacement is performed to 
expose the inferior vena cava (IVC). Genital vein is usually kept in place. The renal 
upper pole is carefully separated from the adrenal as on the left side starting from 
the upper border of the right vein. Renal vessels are also approached from below 
after isolation of the ureter and periureteral fat and identification of the psoas 
muscle and lifting up the kidney. The right renal vein is exposed at its insertion into 
Figure 9. 
Left renal artery and vein stumps after stapling and kidney harvesting. Clips on lymphatics are placed after 
vascular stapling.
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to prevent their later insertion between the jaws of the stapling device leading to 
misfire and serious malfunction [46].
The ureter and its periureteral fat are again lifted up at the level of the iliac 
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surface of the kidney. The ureter is isolated with a generous periureteric fat. After 
completing this posterior release, the kidney is completely lying medially and we 
can free the posterior aspect of the renal artery (Figure 8; Video 6 (https://youtu.
be/xQswiMds4Nc)). Now the kidney is supposed to hold only on the artery, vein, 
and ureter and is ready to be harvested. The patient is given another dose of man-
nitol. An Endocatch bag 15 mm (Covidien) is inserted through the LapCap. The 
distal ureter is clipped and sectioned. A good flow of urine should be noticed before 
pedicle clamping. A number of vascular transfixing stapling devices are available 
for surgeons to secure the renal vessels. The choice of which device to use is down to 
surgeon preference. Recently, we rely on two stapling devices: Endo-TA 30 stapler 
(30-mm length, 2.5-mm staples-Covidien) if maximum length is needed because 
this device delivers three rows of staplers without a cutting knife and no articula-
tion; and vessels are cut with cold scissors; and Echelon Flex™ Powered Vascular 
Stapler 35 mm (Ethicon) with manual articulation for more precise placement, a 
narrow curved blunt tip, and reduction in tip movement during firing; this device 
delivers four rows of staples (instead of six) in a staggered pattern and gives a very 
secure vascular control and less loss in vessel length with nonbloody surgical field 
because of the absent backflow. Stapling starts on the renal artery and then quickly 
on the vein, and the kidney is rapidly placed in the Endo bag and extracted through 
the LapCap (Videos 7 (https://youtu.be/RfIGOjtqpD8) and 8 (https://youtu.be/
dGUKd3R23Yo)). We do not give intravenous heparin prior to vascular occlusion. 
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Spleen separated from the left renal upper pole.
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cheaper than staples. On April 2006, the manufacturer of Weck Hem-o-lok ligating 
clips, Teleflex Medical, added a contraindication to the use of these clips on renal vessels 
in laparoscopic live donor nephrectomy, after receiving 15 medical device reports of 
12 injuries and 3 deaths, all of which occurred between November 19, 2001 and March 
20, 2005. All reports were associated with using the clips for ligation of the renal artery 
during LLDN [47, 48]. Clip dislodgement may occur several hours following the proce-
dure resulting in fatal hemorrhage on the ward [49]. US Food and Drug Administration 
(FDA) issued on May 2011 a warning to healthcare providers that Weck Hem-o-Lok 
ligating clips should not be used for the ligation of the renal artery during LLDN 
because of serious risks and potential life-threatening complications to the donor [50]. 
On the other hand, surgeons must be aware that reported failure rates for staplers are 
3.0% [51]. Stapler misfire rates can be reduced by avoiding the use of titanium and 
other clips around the hilar structures before securing the renal pedicle [46].
Before ending the surgery, latero aortic and inter aorto caval lymphatics are 
clipped (Hem-o-lok clips) to prevent chylous leakage (Video 9 (https://youtu.be/_
c4rjTtvlTw)). Meticulous and extensive clipping remains the safest way of securing 
lymphatic channels along the dissection area despite being usually burned with 
energy-based sealing devices. It has been shown that bipolar cautery can effectively 
ligate and control lymph leakage as also other laparoscopic dissection devices using 
bipolar and ultrasonic energy but monopolar scissors were unreliable with respect 
to sealing lymphatic channels [52, 53]. Last view of the whole surgical field is done 
with particular inspection of the vascular stumps (Figure 9). Pneumoperitoneum is 
exsufflated. No drainage is usually needed. Port and extraction sites are closed.
4.3.2 Right-sided nephrectomy
In some patients, the right side seems to be easier than the left. Steps are almost 
the same. Trocar placement has the same distribution as on the left except for an 
additional 5 mm trocar inserted at the xiphoid for liver retraction (Figure 10). Less 
right colon dissection is needed and careful duodenal displacement is performed to 
expose the inferior vena cava (IVC). Genital vein is usually kept in place. The renal 
upper pole is carefully separated from the adrenal as on the left side starting from 
the upper border of the right vein. Renal vessels are also approached from below 
after isolation of the ureter and periureteral fat and identification of the psoas 
muscle and lifting up the kidney. The right renal vein is exposed at its insertion into 
Figure 9. 
Left renal artery and vein stumps after stapling and kidney harvesting. Clips on lymphatics are placed after 
vascular stapling.
Basic Principles and Practice in Surgery
34
the IVC. Duplication of renal vein is more common on the right side and is reported 
in as much as 15% of potential renal donors [54] (Figure 11). The adrenal vein, 
gonadal vein, and retroperitoneal veins (lumbar, ascending lumbar, and hemiazy-
gos) may drain into the right renal vein in 30, 7, and 3% of cases, respectively [55]. 
The IVC must be well dissected below and above the renal vein to permit later easy 
positioning of the stapler device. In usual anatomy, the renal artery is classically 
found just behind the vein and the space between artery and vein is normally easily 
created. Retrocaval area is a difficult area to work at during LLDN; therefore, the 
exact location of the first segmental branch of right renal artery with respect to the 
IVC should be clearly identified in the pretransplant angio CT scan. In some cases, 
posterior release of the artery behind the IVC is necessary to reach the main trunk 
(Video 10 (https://youtu.be/DPGFtpAVar8)) especially if the artery is in an upper 
position to the vein (Video 11 (https://youtu.be/BfbPdO-U8zU)); or even rarely, 
access to the artery is done through the inter aorto caval space. Caval countertrac-
tion is applied just prior to firing the endovascular stapler, so that adequate venous 
length is obtained. The renal vein is usually 2–3 mm shorter compared with the open 
surgery. Operative time and warm ischemia time may be greater when performing a 
right-sided LLDN, but this does not result in delayed allograft function [56].
5. Postoperative care
The early postoperative period after laparoscopic donor nephrectomy is a 
particular moment in the management of kidney donors. Extubation is done after 
Figure 10. 
Liver retracted through a 5-mm xiphoid trocar.
Figure 11. 
Laparoscopic view of right donor kidney with two veins (V) and one artery (A).
35
Laparoscopic Live Donor Nephrectomy: Techniques and Results
DOI: http://dx.doi.org/10.5772/intechopen.80880
normothermic state. Orogastric tube is removed prior to extubation. Hemoglobin 
measurement is realized every 6 h postsurgery, and if normal, it will be repeated the 
next morning with serum creatinine and electrolytes. Urine output is monitored. 
Shoulder tip discomfort and pain is a major complaint after LLDN perhaps from 
residual pneumoperitoneum. Epidural analgesia is ineffective for shoulder pain. 
There has been collective belief to aggressively minimize pain postoperatively in this 
special category of patients who are usually narcotics naïve. IV “patient-controlled 
analgesia” (PCA; fentanyl or morphine less commonly) was considered to be the 
modality of choice to achieve that. If PCA is not available, pain control is achieved 
with IV paracetamol and if needed ketoprofen or ketorolac over the first 24 h [57]. To 
reduce the risk of nephrotoxicity, the patient should be kept well hydrated. Opiates 
also have an effective role for breakthrough pain when opiate-sparing strategies have 
not been effective. Clear liquids are started on the day of surgery with increase of 
diet later. The emergence of enhanced recovery after surgery (ERAS) brought major 
changes to the traditional standard of care. Many centers across the USA have adopted 
the enhanced recovery programs that include intraoperative fluid restriction to 3 ml/
kg/h preventing excessive third spacing and bowel edema, urine output of 0.5 ml/
kg/h, use of local subfascial bupivacaine or other anesthetics as well as a postoperative 
narcotic-free pain control regimen, i.e., acetaminophen, ketorolac, etc. [58]. Novelties 
in this management were associated with reduced length of hospital stay, better pain 
control, and increased patient satisfaction. It has become evident that ERAS would 
potentially enhance the benefits of laparoscopic surgery for kidney donors [59].
Foley catheter is removed on the morning of day 1 and ambulation started as 
soon as possible either during the evening of day 0 or the next morning. Living 
kidney donors are classified as “medium risk” patients for deep venous thrombosis 
(DVT) and pulmonary embolism [4]. All living donors must have intra- and post-
operative compression stockings and should receive adequate thromboprophylaxis 
with low-molecular weight-heparin and continuing for at least 1 week. Patient is 
discharged most frequently on day 2 and seen back 10 days later with a follow-up at 
6 months, 1 year, and 2 years after donation. Donors must resume a normal life-
style as soon as possible with regular surveillance of their blood pressure and their 
weight. They should be warned about avoiding nephrotoxic medications.
6. Complications
LLDN appears to be a safe procedure or at least as safe as the open one. But 
serious complications including death may occur. Overall mortality rate is approxi-
mately 0.03% [34] although some large series reported no mortality [60–63]. 
Most of these deaths occurred in the postoperative period and were due to hemor-
rhage [47], CO2 gas embolism [64], and pulmonary embolism [34]. The risk of 
a major intraoperative hemorrhage during LLDN is between 0.6 and 1.6% [60, 
63]. Conversion to open surgery has been reported to occur in 0 to 13% of cases, 
but in most large series, conversion rates of 1–2% are reported [4, 60–63]. Other 
intraoperative complications are splenic or liver laceration, ureteral and intestinal 
injury, and pleural laceration. The total incidence of surgical complications is 5.46% 
[61]. All major complications occurred in the first 100 cases [62]. This raises the 
question of the learning curve and how many laparoscopic nephrectomies should 
be done before performing the first LLDN? There is no precise answer but a number 
between 50 and 100 seems to be convincing for this type of surgery to be learned.
Postoperative complications of LLDN are hematomas, fever, urinary tract 
infection, pneumonia, pulmonary embolism, wound infection, incisional hernias, 
prolonged ileus, chylous ascites, and left testicular pain perhaps due to gonadal vein 
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gos) may drain into the right renal vein in 30, 7, and 3% of cases, respectively [55]. 
The IVC must be well dissected below and above the renal vein to permit later easy 
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found just behind the vein and the space between artery and vein is normally easily 
created. Retrocaval area is a difficult area to work at during LLDN; therefore, the 
exact location of the first segmental branch of right renal artery with respect to the 
IVC should be clearly identified in the pretransplant angio CT scan. In some cases, 
posterior release of the artery behind the IVC is necessary to reach the main trunk 
(Video 10 (https://youtu.be/DPGFtpAVar8)) especially if the artery is in an upper 
position to the vein (Video 11 (https://youtu.be/BfbPdO-U8zU)); or even rarely, 
access to the artery is done through the inter aorto caval space. Caval countertrac-
tion is applied just prior to firing the endovascular stapler, so that adequate venous 
length is obtained. The renal vein is usually 2–3 mm shorter compared with the open 
surgery. Operative time and warm ischemia time may be greater when performing a 
right-sided LLDN, but this does not result in delayed allograft function [56].
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normothermic state. Orogastric tube is removed prior to extubation. Hemoglobin 
measurement is realized every 6 h postsurgery, and if normal, it will be repeated the 
next morning with serum creatinine and electrolytes. Urine output is monitored. 
Shoulder tip discomfort and pain is a major complaint after LLDN perhaps from 
residual pneumoperitoneum. Epidural analgesia is ineffective for shoulder pain. 
There has been collective belief to aggressively minimize pain postoperatively in this 
special category of patients who are usually narcotics naïve. IV “patient-controlled 
analgesia” (PCA; fentanyl or morphine less commonly) was considered to be the 
modality of choice to achieve that. If PCA is not available, pain control is achieved 
with IV paracetamol and if needed ketoprofen or ketorolac over the first 24 h [57]. To 
reduce the risk of nephrotoxicity, the patient should be kept well hydrated. Opiates 
also have an effective role for breakthrough pain when opiate-sparing strategies have 
not been effective. Clear liquids are started on the day of surgery with increase of 
diet later. The emergence of enhanced recovery after surgery (ERAS) brought major 
changes to the traditional standard of care. Many centers across the USA have adopted 
the enhanced recovery programs that include intraoperative fluid restriction to 3 ml/
kg/h preventing excessive third spacing and bowel edema, urine output of 0.5 ml/
kg/h, use of local subfascial bupivacaine or other anesthetics as well as a postoperative 
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injury, and pleural laceration. The total incidence of surgical complications is 5.46% 
[61]. All major complications occurred in the first 100 cases [62]. This raises the 
question of the learning curve and how many laparoscopic nephrectomies should 
be done before performing the first LLDN? There is no precise answer but a number 
between 50 and 100 seems to be convincing for this type of surgery to be learned.
Postoperative complications of LLDN are hematomas, fever, urinary tract 
infection, pneumonia, pulmonary embolism, wound infection, incisional hernias, 
prolonged ileus, chylous ascites, and left testicular pain perhaps due to gonadal vein 
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division or extensive mobilization of the left colon which may damage the neural 
plexus supplying the testis and may also disrupt lymphatic drainage [65]. Chylous 
leakage is a rare complication of LLDN. Prevention is assured by doing a meticulous 
and extensive clipping of lymphatic channels along the dissection area [52, 66].
Long-term complications are arterial hypertension, renal failure, and protein-
uria, particularly in more high-risk donors, such as those with obesity, old or young 
donors, hypertensive donors, and those with kidney stones [67, 68]. Following 
kidney donation, there is a compensatory increase in function in the remaining 
kidney. By 3 months, remnant kidney clearance increases to a mean GFR of around 
65–75% of predonation renal function [4]. The average decrease in GFR after dona-
tion was 26 mL/min/1.73 m2 (range 8–50) [4, 69]. The incidence of end-stage renal 
disease (ESRD) in living kidney donors appears to be similar to or lower than that 
seen in the unselected general population despite a reduction in GFR [4, 24, 70]. 
The estimated lifetime risk of ESRD was 90 per 10,000 in donors, 326 per 10,000 in 
the general population, and 14 per 10,000 in matched healthy nondonor controls 
[71]. Live donor nephrectomy alone will not lead to renal failure [72].
Concerning hypertension, a large meta-analysis demonstrated that donors have 
an increased systolic blood pressure of 5 mmHg after 5–10 years from donation 
[73]. The rate of hypertension in donors was similar to that of the general popula-
tion [74]. But it seems that there are no effects on kidney function and microalbu-
minuria at least in Caucasian population. Blacks and Hispanics may have higher 
risks of hypertension-associated kidney disease after donation [75, 76].
Finally, it is interesting to know that longevity of live donors remains greater 
compared to the general population [24, 72, 77].
7. Conclusion
Living donation is a success story that saved many patients with end-stage renal 
disease from dialysis and offered them a better quality of life and longer life expec-
tancy. Donor surgery has shifted from the old open technique to a mini-invasive 
approach that offers less pain to this category of people who are not true patients 
but true heroes full of courage and nobility. Ensuring the safety and excellent 
long-term outcomes of these donors is our duty, through all steps from preoperative 
workup, surgery, and postoperative care.
Donors must be aware of all potential complications before acceptance and 
should feel free to resign at any moment. Complications of LLDN are present and 
must be prevented by entrusting them to highly qualified and experienced surgeons.
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Abstract
In assisting a patient with adrenocortical tumors, the main concern is to 
establish whether the lesion consists of a malignant neoplasm and if there is any 
hormonal functioning, which are two instances that generally demand surgery. In 
distinguishing benign from malignant lesions, two aspects are particularly impor-
tant: the size of the lesion and the image findings. In order to establish whether a 
lesion is hormonally functioning, it is necessary to carry out thorough clinical and 
endocrine assessments. The extension of such assessments is still controversial. This 
present chapter revises fundamental aspects of the propaedeutic of such tumors. 
Most guidelines agree that lesions smaller than 1 cm need not be investigated. The 
diagnostic and therapeutic approach of adrenocortical tumors imposes a difficult 
and challenging dilemma in terms of its approach, as it may be a benign finding or it 
may imply a high level of morbidity and mortality due to its hormonal activity or a 
possible malignant histology.
Keywords: adrenocortical tumors, adenoma, adrenal, Cushing’s syndrome, 
aldosteronoma
1. Introduction
Adrenal gland tumors are common entities in clinical practice. They are divided 
as functioning (which produces hormones) and the nonfunctioning ones (also 
known as silent). In terms of their biological behavior, they may be divided in 
benign or malignant tumors. The term “incidentaloma” refers to adrenal masses 
that are found in image exams aiming at investigating disturbances unrelated to the 
adrenal glands [1–3].
Most adrenocortical tumors are benign, unilateral, nonfunctioning adenomas 
with less than 4 cm in diameter that are found during abdominal image studies [3]. 
The functioning adrenal tumors are generally the benign adenoma type, which 
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1. Introduction
Adrenal gland tumors are common entities in clinical practice. They are divided 
as functioning (which produces hormones) and the nonfunctioning ones (also 
known as silent). In terms of their biological behavior, they may be divided in 
benign or malignant tumors. The term “incidentaloma” refers to adrenal masses 
that are found in image exams aiming at investigating disturbances unrelated to the 
adrenal glands [1–3].
Most adrenocortical tumors are benign, unilateral, nonfunctioning adenomas 
with less than 4 cm in diameter that are found during abdominal image studies [3]. 
The functioning adrenal tumors are generally the benign adenoma type, which 
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cause, for instance, the Cushing’s syndrome, primary aldosteronism, or, not so 
commonly, virilization [1, 2].
This present chapter discusses the preoperative assessment of patients suffering 
from this condition. It mainly focuses on:
1. Whether there is hormonal production by the tumor and the controlling 
techniques
2. The malignancy risk and the staging for propaedeutic planning purposes
2. Epidemiology
The frequency of adrenocortical tumor diagnosis has increased nowadays due 
to larger availability of image examination techniques, which makes it a relatively 
common clinical problem currently. Some studies claim a detection rate of 4% in all 
abdominal computer tomography [4]. Studies in series of autopsies identified that 
adrenal masses count less than 1% in individuals younger than 30 years of age and 
that the rate increases to 7% in those who were 70 or older [1, 2].
Adrenocortical tumors are more common in white, obese, diabetic, and 
hypertensive individuals. These data might be biased, as elderly, white individu-
als constitute the groups that most frequently undergo image examinations. It is 
known that such tumors are rather uncommon in individuals under 50 years of age 
and are especially uncommon in children [2]. They are more common on the right 
side [2, 3].
In terms of hormonal production, even though most tumors are nonfunctioning, in 
up to 15% of cases, there might be a slightly increased production of certain hormones, 
being cortisol the most common one, which may cause Cushing’s syndrome [1].
Around 10–15% of all tumors found are bilateral [2]. Bilateral functioning adre-
nocortical masses may be congenital adrenal hyperplasia due to a 21-hydroxylase 
deficiency, adrenal macronodular hyperplasia, or primary hyperaldosteronism [2].
The most common causes of bilateral nonfunctioning adrenal masses are metas-
tases, infections (mycosis, tuberculosis), lymphomas, bleedings, amyloidosis, and, 
rather rarely, carcinoma and myelolipomas [1].
In a decreasing order of occurrence, the adrenocortical tumor categories are:
1. Nonfunctioning adenomas (43–75%)
2. Cortisol-producing adenomas (including subclinical Cushing’s syndrome) 
(10–15%)
3. Myelolipomas (6–8%)
4. Adrenal carcinomas (4–11%)
5. Metastatic lesions (3–10%)
6. Aldosteronomas (2–6%)
7. Cyst (5%)
8. Tuberculosis and lymphomas (3–8%)
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3. Natural history
Natural history of adrenocortical tumors is still not completely known [1]. Some 
studies suggest that most incidentalomas remain within stable size for many years 
[2]. Long-term follow-up studies suggest that from 5 to 20% of cases involving 
tumors larger than 1 cm, there is an increase in adrenal mass after an average period 
of 4 years, regardless of the state of adrenal hormonal production [1]. The typical 
increase rate of an adrenocortical carcinoma exceeds 2 cm per year, with a survival 
expectation lower than 50% within 5 years [1, 2].
Occasionally, tumor reduction might be observed (3–4% of cases). Appearance 
of mass at the contralateral gland might also be noticed. Nonetheless, the risk of 
malignancy development is low (<1/1000) [1].
There is a risk that a nonfunctioning adenoma starts to produce some hormone 
during follow-up, especially if the mass is larger than 3 cm and mainly in the case of 
cortisol production. Prospective studies show a 0.3% risk of a subclinical Cushing’s 
syndrome development and a 0.2% chance of it turning into a pheochromocytoma. 
After a 3- to 4-year follow-up, such risk reaches a plateau that is to say the possibil-
ity that it would turn into a functioning one is low. Therefore, repetition of screen-
ing for functioning is only prescribed during the first 5 years of follow-up [2].
For the reasons explained here, rather small nodules (smaller than 1 cm) with 
a benign tomographic aspect need not be further investigated by image, as the 
benignity chance is high, whereas the risk of growth is low [2].
4. Pathological findings
Adrenal adenomas are generally encapsulated, have variable volume and weight, 
and in most cases have a diameter of 2–4 cm. In nonfunctioning tumors, clear cells 
of the fasciculate zone, filled with lipids (cholesterol), predominate microscopi-
cally, which gives the yellowish coloration. Functioning tumors are usually of varied 
colors, reddish-brown, with yellowish areas or striae, showing in microscopy the 
predominance of compact cells, associated with clear cell nests (Figure 1). Cortisol-
producing adenomas are accompanied by hypotrophy of the adrenal cortex of 
the affected gland and the contralateral adrenal gland due to adrenocorticotropic 
hormone (ACTH) (suppression in contrast to aldosterone-producing adenomas in 
which this aspect is not observed) [3].
Figure 1. 
Microscopy of an adrenal cortex adenoma showing one or more cell types (A) separated from each other 
by fibrous septa containing blood vessels (H&E 100×). High increase showing cells in the zona glomerulosa, 
fasciculate zone, and reticular zone forming nests and strands (H&E 400×).
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tases, infections (mycosis, tuberculosis), lymphomas, bleedings, amyloidosis, and, 
rather rarely, carcinoma and myelolipomas [1].
In a decreasing order of occurrence, the adrenocortical tumor categories are:
1. Nonfunctioning adenomas (43–75%)
2. Cortisol-producing adenomas (including subclinical Cushing’s syndrome) 
(10–15%)
3. Myelolipomas (6–8%)
4. Adrenal carcinomas (4–11%)
5. Metastatic lesions (3–10%)
6. Aldosteronomas (2–6%)
7. Cyst (5%)
8. Tuberculosis and lymphomas (3–8%)
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3. Natural history
Natural history of adrenocortical tumors is still not completely known [1]. Some 
studies suggest that most incidentalomas remain within stable size for many years 
[2]. Long-term follow-up studies suggest that from 5 to 20% of cases involving 
tumors larger than 1 cm, there is an increase in adrenal mass after an average period 
of 4 years, regardless of the state of adrenal hormonal production [1]. The typical 
increase rate of an adrenocortical carcinoma exceeds 2 cm per year, with a survival 
expectation lower than 50% within 5 years [1, 2].
Occasionally, tumor reduction might be observed (3–4% of cases). Appearance 
of mass at the contralateral gland might also be noticed. Nonetheless, the risk of 
malignancy development is low (<1/1000) [1].
There is a risk that a nonfunctioning adenoma starts to produce some hormone 
during follow-up, especially if the mass is larger than 3 cm and mainly in the case of 
cortisol production. Prospective studies show a 0.3% risk of a subclinical Cushing’s 
syndrome development and a 0.2% chance of it turning into a pheochromocytoma. 
After a 3- to 4-year follow-up, such risk reaches a plateau that is to say the possibil-
ity that it would turn into a functioning one is low. Therefore, repetition of screen-
ing for functioning is only prescribed during the first 5 years of follow-up [2].
For the reasons explained here, rather small nodules (smaller than 1 cm) with 
a benign tomographic aspect need not be further investigated by image, as the 
benignity chance is high, whereas the risk of growth is low [2].
4. Pathological findings
Adrenal adenomas are generally encapsulated, have variable volume and weight, 
and in most cases have a diameter of 2–4 cm. In nonfunctioning tumors, clear cells 
of the fasciculate zone, filled with lipids (cholesterol), predominate microscopi-
cally, which gives the yellowish coloration. Functioning tumors are usually of varied 
colors, reddish-brown, with yellowish areas or striae, showing in microscopy the 
predominance of compact cells, associated with clear cell nests (Figure 1). Cortisol-
producing adenomas are accompanied by hypotrophy of the adrenal cortex of 
the affected gland and the contralateral adrenal gland due to adrenocorticotropic 
hormone (ACTH) (suppression in contrast to aldosterone-producing adenomas in 
which this aspect is not observed) [3].
Figure 1. 
Microscopy of an adrenal cortex adenoma showing one or more cell types (A) separated from each other 
by fibrous septa containing blood vessels (H&E 100×). High increase showing cells in the zona glomerulosa, 
fasciculate zone, and reticular zone forming nests and strands (H&E 400×).
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Adrenal carcinomas are usually larger than 4 cm and occasionally weigh more 
than 1 kg. Microscopically, the picture is varied: in some cases, the tumor is very 
similar to the adenoma, but in some cases, the tumor appears anaplastically, being 
composed of cells with large pleomorphism, bizarre nuclei, and atypical mitoses. 
Vascular or capsular invasion is a predictive sign of malignant behavior, being a sign 
of local extension [3, 4].
Differentiation with adenomas can be difficult and is based on macroscopic 
(tumor weight, hemorrhage, and capsule integrity) and microscopic aspects using 
the modified Weiss scoring system. The five criteria used in the updated Weiss sys-
tem include >6 mitoses/50 high potency fields, ≤25% clear tumor cells in the cyto-
plasm, abnormal mitoses, necrosis, and capsular invasion. Each criterion is scored 0 
when absent or 2 for the first two criteria and 1 for the last three when present. The 
adrenal carcinoma can be diagnosed by the presence of a total score ≥ 3 [5].
Tumors are functioning in approximately 60% of all cases, but the presence 
of symptoms of hormonal hypersecretion is present in only 40%, possibly by the 
secretion of large quantities of biologically inactive hormones [5, 6].
In general, adrenal carcinomas rarely produce and secrete a single steroid 
hormone and are usually associated with overproduction and hypersecretion of 
multiple hormones and precursors. Most cases produce different types of steroid 
hormones [7–9]. Thus, hypersecretion of a single adrenocortical steroid usually 
indicates the benign nature of adrenocortical neoplasia. The most frequently seen 
combination is hypersecretion of cortisol and androgens [10].
5. Hormone assessment
There are basically three types of production by adrenocortical tumors:
1. Cortisol (corresponding to between 5 and 20% of cases)
2. Aldosterone (corresponding to 1% of cases)
3. Androgen (extremely rare)
5.1 Cortisol-producing tumors
Such tumors generally produce minute quantities of cortisol, which, most 
of times, do not suffice to increase the excretion of free cortisol in urine. They 
are, nonetheless, able to cause suppression of the hypothalamic-pituitary axis. 
Ordinarily, there are no Cushing-related manifestations in those patients. For 
that reason, this condition has been known as subclinical Cushing’s syndrome or 
subclinical hypercortisolism [11]. There might be the classic Cushing’s syndrome in 
long-evolving cases.
A suppression test with 1 mg of dexamethasone should be carried out at night 
for tracking Cushing’s syndrome. The patient orally takes 1 mg of dexamethasone 
at 11:00 pm the night prior to sample collection of plasmatic cortisol, which is to 
be carried out at 8:00 am the following morning. Values that determine abnormal 
response of cortisol in this test varied in several studies from 1.8 to 5.0 mcg/dL, yet 
most guidelines lead to the following interpretation:
Levels of plasmatic cortisol <1.8 mcg/dL virtually exclude autonomous produc-
tion of cortisol, with sensitivity >95% and specificity from 70 to 80%.
Cortisol levels between 1.8 and 5 mcg/dL have been considered to be 
undetermined.
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Values >5 mcg/dL would indicate a highly probable diagnosis of Cushing’s 
syndrome (specificity > 95%) [1].
An abnormal suppression of 1 mg of dexamethasone during the night is consistent 
with a positive tracking, and it should be confirmed by a 24-hour free urinary corti-
sol, which should then be followed by an investigation of the serum dosage of cortisol 
after a high dose (8 mg) of dexamethasone during the night and the serum dosage 
ACTH [3, 4]. This latter investigation aims at determining the origin of the Cushing’s 
syndrome, as to refute a hypopituitary cause. This condition is typically presented 
with unsuppressed levels (ACTH dependent). For diagnosis of subclinical Cushing’s 
syndrome, many experts propose confirmation under the following criteria:
Values > 5 mcg/dL in plasmatic cortisol at the 1 mg dexamethasone test without 
any other stigma
OR
At least two from the following results:
Levels of plasmatic ACTH < 10 pg/ml with an increased 24-hour free urinary 
cortisol and values > 3 mcg/dL of plasmatic cortisol at the 1 mg dexamethasone test 
[1]. Figure 2 shows an algorithm of investigation of Cushing’s syndrome.
Dehydroepiandrosterone sulfate is an adrenal androgen that is produced under 
stimulus of ACTH. Thus, an undetectable concentration of dehydroepiandrosterone 
sulfate in serum suggests a chronical suppression of ACTH levels [12].
Percentage of patients suffering from subclinical Cushing’s syndrome that would 
evolve to the classic Cushing’s syndrome is uncertain. It is estimated to be <1%, 
though [1].
Even though patients suffering from subclinical Cushing’s syndrome do not 
present the classic stigmata related to hypercortisolism, they present, as suggested in 
some studies, in comparison with the population in general, higher occurrences of:
• Hypertension (40–90%)




An increase in the carotid intima-media thickness has been recently reported, 
as well as alteration of coagulation parameters, decrease in the quality of life, and 
occurrences of mortality due to cardiovascular disease [1].
For those reasons, there is still no consensus about the approach to subclinical 
Cushing’s syndrome. It may be treated clinically or through surgery [2].
Generally, in cases with many occurrences of comorbidity that might be attrib-
uted to hypercortisolism, such as systemic arterial hypertension, diabetes mellitus, 
dyslipidemia, osteoporosis, and central obesity, especially the ones that are difficult 
to control, a ponderation of the risk/benefit of surgical treatment by adrenalectomy 
of the affected adrenal should be carried out, as proposed for the treatment of clas-
sic Cushing’s syndrome [2].
It is important to mention that up to 75% of patients might develop acute adrenal 
insufficiency (sometimes deadly) at the post-surgery phase of adrenalectomy in 
case they are not treated with glucocorticoid due to atrophy of the contralateral 
gland. This should be an additional functional endocrine characterization for the 
propaedeutic planning [1]. In case the adrenalectomy is carried out, there should be 
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Adrenal carcinomas are usually larger than 4 cm and occasionally weigh more 
than 1 kg. Microscopically, the picture is varied: in some cases, the tumor is very 
similar to the adenoma, but in some cases, the tumor appears anaplastically, being 
composed of cells with large pleomorphism, bizarre nuclei, and atypical mitoses. 
Vascular or capsular invasion is a predictive sign of malignant behavior, being a sign 
of local extension [3, 4].
Differentiation with adenomas can be difficult and is based on macroscopic 
(tumor weight, hemorrhage, and capsule integrity) and microscopic aspects using 
the modified Weiss scoring system. The five criteria used in the updated Weiss sys-
tem include >6 mitoses/50 high potency fields, ≤25% clear tumor cells in the cyto-
plasm, abnormal mitoses, necrosis, and capsular invasion. Each criterion is scored 0 
when absent or 2 for the first two criteria and 1 for the last three when present. The 
adrenal carcinoma can be diagnosed by the presence of a total score ≥ 3 [5].
Tumors are functioning in approximately 60% of all cases, but the presence 
of symptoms of hormonal hypersecretion is present in only 40%, possibly by the 
secretion of large quantities of biologically inactive hormones [5, 6].
In general, adrenal carcinomas rarely produce and secrete a single steroid 
hormone and are usually associated with overproduction and hypersecretion of 
multiple hormones and precursors. Most cases produce different types of steroid 
hormones [7–9]. Thus, hypersecretion of a single adrenocortical steroid usually 
indicates the benign nature of adrenocortical neoplasia. The most frequently seen 
combination is hypersecretion of cortisol and androgens [10].
5. Hormone assessment
There are basically three types of production by adrenocortical tumors:
1. Cortisol (corresponding to between 5 and 20% of cases)
2. Aldosterone (corresponding to 1% of cases)
3. Androgen (extremely rare)
5.1 Cortisol-producing tumors
Such tumors generally produce minute quantities of cortisol, which, most 
of times, do not suffice to increase the excretion of free cortisol in urine. They 
are, nonetheless, able to cause suppression of the hypothalamic-pituitary axis. 
Ordinarily, there are no Cushing-related manifestations in those patients. For 
that reason, this condition has been known as subclinical Cushing’s syndrome or 
subclinical hypercortisolism [11]. There might be the classic Cushing’s syndrome in 
long-evolving cases.
A suppression test with 1 mg of dexamethasone should be carried out at night 
for tracking Cushing’s syndrome. The patient orally takes 1 mg of dexamethasone 
at 11:00 pm the night prior to sample collection of plasmatic cortisol, which is to 
be carried out at 8:00 am the following morning. Values that determine abnormal 
response of cortisol in this test varied in several studies from 1.8 to 5.0 mcg/dL, yet 
most guidelines lead to the following interpretation:
Levels of plasmatic cortisol <1.8 mcg/dL virtually exclude autonomous produc-
tion of cortisol, with sensitivity >95% and specificity from 70 to 80%.
Cortisol levels between 1.8 and 5 mcg/dL have been considered to be 
undetermined.
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Values >5 mcg/dL would indicate a highly probable diagnosis of Cushing’s 
syndrome (specificity > 95%) [1].
An abnormal suppression of 1 mg of dexamethasone during the night is consistent 
with a positive tracking, and it should be confirmed by a 24-hour free urinary corti-
sol, which should then be followed by an investigation of the serum dosage of cortisol 
after a high dose (8 mg) of dexamethasone during the night and the serum dosage 
ACTH [3, 4]. This latter investigation aims at determining the origin of the Cushing’s 
syndrome, as to refute a hypopituitary cause. This condition is typically presented 
with unsuppressed levels (ACTH dependent). For diagnosis of subclinical Cushing’s 
syndrome, many experts propose confirmation under the following criteria:
Values > 5 mcg/dL in plasmatic cortisol at the 1 mg dexamethasone test without 
any other stigma
OR
At least two from the following results:
Levels of plasmatic ACTH < 10 pg/ml with an increased 24-hour free urinary 
cortisol and values > 3 mcg/dL of plasmatic cortisol at the 1 mg dexamethasone test 
[1]. Figure 2 shows an algorithm of investigation of Cushing’s syndrome.
Dehydroepiandrosterone sulfate is an adrenal androgen that is produced under 
stimulus of ACTH. Thus, an undetectable concentration of dehydroepiandrosterone 
sulfate in serum suggests a chronical suppression of ACTH levels [12].
Percentage of patients suffering from subclinical Cushing’s syndrome that would 
evolve to the classic Cushing’s syndrome is uncertain. It is estimated to be <1%, 
though [1].
Even though patients suffering from subclinical Cushing’s syndrome do not 
present the classic stigmata related to hypercortisolism, they present, as suggested in 
some studies, in comparison with the population in general, higher occurrences of:
• Hypertension (40–90%)




An increase in the carotid intima-media thickness has been recently reported, 
as well as alteration of coagulation parameters, decrease in the quality of life, and 
occurrences of mortality due to cardiovascular disease [1].
For those reasons, there is still no consensus about the approach to subclinical 
Cushing’s syndrome. It may be treated clinically or through surgery [2].
Generally, in cases with many occurrences of comorbidity that might be attrib-
uted to hypercortisolism, such as systemic arterial hypertension, diabetes mellitus, 
dyslipidemia, osteoporosis, and central obesity, especially the ones that are difficult 
to control, a ponderation of the risk/benefit of surgical treatment by adrenalectomy 
of the affected adrenal should be carried out, as proposed for the treatment of clas-
sic Cushing’s syndrome [2].
It is important to mention that up to 75% of patients might develop acute adrenal 
insufficiency (sometimes deadly) at the post-surgery phase of adrenalectomy in 
case they are not treated with glucocorticoid due to atrophy of the contralateral 
gland. This should be an additional functional endocrine characterization for the 
propaedeutic planning [1]. In case the adrenalectomy is carried out, there should be 
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a perioperative coverage of glucocorticoid due to the risk of adrenal insufficiency, 
hemodynamic crisis, and death [12].
Weight loss, improvement of hypertension, glycemic control, and normalization 
of bone renewal markers are frequently found in the post unilateral adrenalectomy 
scenario of patients with subclinical or classic Cushing’s syndrome [12].
5.2 Aldosterone-producing tumors
Also known as aldosteronomas, they are rare (less than 1% of cases), and 
their characteristic manifestation is systemic arterial hypertension associated 
with hypokalemia. Yet primary normocalcemic hyperaldosteronism is common 
(20–50% of cases) [1, 12]. For that reason, as most patients suffering from 
primary aldosteronism do not suffer from hypocalcemia, all patients suffer-
ing from hypertension and adrenal incidentaloma should be assessed through 
measurements of their aldosterone plasmatic concentration and plasma renin 
activity [12].
Initial endocrine investigation in such cases consists of dosing the levels of 
plasma aldosterone and plasma renin activity. In case the ratio between them is <27, 
the existence of hyperaldosteronism is virtually excluded. Other authors use further 
landmarks (between 20 and 30) to establish diagnosis as abnormal. Values >40–50 
are almost hyperaldosteronism pathognomonic [1].
It is important to mention that if the laboratory can only assess the renin direct 
dosage (other than the plasma renin activity), the renin value must be divided by 
12, so that the actual value of plasma renin activity is established, which will even-
tually be the one used for the ratio calculation. If the ratio is lower than 20, it can 
refute diagnosis. In case it is between 20 and 30, it indicates a likely diagnosis. Then, 
if it exceeds 30, with aldosterone dosage higher than 15 ng/dl, positive tracing 
should be considered and investigation should continue through tests for confirma-
tion [2]. In patients with spontaneous hypokalemia, plasma renin below detection 
Figure 2. 
An algorithm for investigation of Cushing’s syndrome in adrenal incidentalomas. Dexa, dexamethasone; SC, 
serum cortisol; UFC, urine-free cortisol; ACTH, adrenocorticotropic hormone. *At least two measurements.
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levels plus plasma aldosterone >20 ng/dL, it is suggested that there is no need for 
further confirmatory testing (Figure 3) [4].
The aldosterone and plasma renin activity relationship should never be used for 
patients under spironolactone, and in case doubtful results appear, other medica-
tions (a beta blocker, central alpha-adrenergic agonist, anti-inflammatory) that 
might cause a false increase of that relationship should ideally be suspended, as well 
as those drugs that cause a false reduction of the inhibitors of angiotensin-converting 
enzyme, aldosterone receptor blocker, thiazide, and dihydropyridine inhibitors of 
the calcium channel [2].
Patients older than 40 years of age suffering from confirmed hyperaldosteron-
ism, even with evidence of adrenal images compactible with such diagnosis, should 
be submitted to adrenal catheterization for assessment of whether that increased 
aldosterone production is really due to incidentaloma or to adrenal hyperplasia, 
whereas the occurrence of nonfunctioning incidentalomas in the population older 
than 40 is no longer negligible (around 4%).
In such cases, adrenalectomy would not solve hormonal hyperproduction, which 
should be kept under control with the use of medication, aldosterone antagonists, 
such as spironolactone [2].
5.3 Androgen- and estrogen-producing tumors
In cases of congenital adrenal hyperplasia due to a 21-hydroxylase deficiency, it 
is rather common to find adrenal masses, either uni- or bilateral ones, presumably 
due to excessive chronic stimulation of adrenals by ACTH [1].
Sex-hormone-producing adrenal adenomas are very rare. Androgen-producing 
carcinomas are also uncommon. Nevertheless, patients generally manifest some 
virilization, which makes it unlikely for such tumors to be related to adrenal 
incidentalomas. Thus, the routine testosterone and estradiol dosage are not rec-
ommended for patients with adrenocortical incidentalomas who present trace of 
Figure 3. 
Algorithm for investigation of hyperaldosteronism in adrenal incidentalomas. *Most commonly used 
confirmatory tests: oral sodium loading test and intravenous saline infusion test. #In patients with spontaneous 
hypokalemia, plasma renin below detection levels plus plasma aldosterone > 20 ng/dl, it is suggested that there 
is no need for further confirmatory testing.
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a perioperative coverage of glucocorticoid due to the risk of adrenal insufficiency, 
hemodynamic crisis, and death [12].
Weight loss, improvement of hypertension, glycemic control, and normalization 
of bone renewal markers are frequently found in the post unilateral adrenalectomy 
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their characteristic manifestation is systemic arterial hypertension associated 
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(20–50% of cases) [1, 12]. For that reason, as most patients suffering from 
primary aldosteronism do not suffer from hypocalcemia, all patients suffer-
ing from hypertension and adrenal incidentaloma should be assessed through 
measurements of their aldosterone plasmatic concentration and plasma renin 
activity [12].
Initial endocrine investigation in such cases consists of dosing the levels of 
plasma aldosterone and plasma renin activity. In case the ratio between them is <27, 
the existence of hyperaldosteronism is virtually excluded. Other authors use further 
landmarks (between 20 and 30) to establish diagnosis as abnormal. Values >40–50 
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dosage (other than the plasma renin activity), the renin value must be divided by 
12, so that the actual value of plasma renin activity is established, which will even-
tually be the one used for the ratio calculation. If the ratio is lower than 20, it can 
refute diagnosis. In case it is between 20 and 30, it indicates a likely diagnosis. Then, 
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should be considered and investigation should continue through tests for confirma-
tion [2]. In patients with spontaneous hypokalemia, plasma renin below detection 
Figure 2. 
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levels plus plasma aldosterone >20 ng/dL, it is suggested that there is no need for 
further confirmatory testing (Figure 3) [4].
The aldosterone and plasma renin activity relationship should never be used for 
patients under spironolactone, and in case doubtful results appear, other medica-
tions (a beta blocker, central alpha-adrenergic agonist, anti-inflammatory) that 
might cause a false increase of that relationship should ideally be suspended, as well 
as those drugs that cause a false reduction of the inhibitors of angiotensin-converting 
enzyme, aldosterone receptor blocker, thiazide, and dihydropyridine inhibitors of 
the calcium channel [2].
Patients older than 40 years of age suffering from confirmed hyperaldosteron-
ism, even with evidence of adrenal images compactible with such diagnosis, should 
be submitted to adrenal catheterization for assessment of whether that increased 
aldosterone production is really due to incidentaloma or to adrenal hyperplasia, 
whereas the occurrence of nonfunctioning incidentalomas in the population older 
than 40 is no longer negligible (around 4%).
In such cases, adrenalectomy would not solve hormonal hyperproduction, which 
should be kept under control with the use of medication, aldosterone antagonists, 
such as spironolactone [2].
5.3 Androgen- and estrogen-producing tumors
In cases of congenital adrenal hyperplasia due to a 21-hydroxylase deficiency, it 
is rather common to find adrenal masses, either uni- or bilateral ones, presumably 
due to excessive chronic stimulation of adrenals by ACTH [1].
Sex-hormone-producing adrenal adenomas are very rare. Androgen-producing 
carcinomas are also uncommon. Nevertheless, patients generally manifest some 
virilization, which makes it unlikely for such tumors to be related to adrenal 
incidentalomas. Thus, the routine testosterone and estradiol dosage are not rec-
ommended for patients with adrenocortical incidentalomas who present trace of 
Figure 3. 
Algorithm for investigation of hyperaldosteronism in adrenal incidentalomas. *Most commonly used 
confirmatory tests: oral sodium loading test and intravenous saline infusion test. #In patients with spontaneous 
hypokalemia, plasma renin below detection levels plus plasma aldosterone > 20 ng/dl, it is suggested that there 
is no need for further confirmatory testing.
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virilization [1]. For individuals that present such virilization or high concentrations 
of androgens, adrenalectomy may be indicated for controlling of hormones.
Estrogen-producing tumors are rare and they are generally malignant. In men, it 
may manifest through feminization with gynecomastia, decrease in libido, atrophy 
of testicles, whereas in women, it could manifest through breast sensitivity and 
bleedings [12]. In such cases, adrenalectomy may also be indicated.
6. Adrenal image
As previously mentioned, most adrenocortical tumors are benign, nonfunction-
ing adenomas that were incidentally found in abdominal image examinations such 
as computed tomography and abdomen magnetic resonance imaging.
Adrenal incidentalomas rarely have a malign cause in patients with no known 
record of cancer. It is estimated that only 2–5% of incidentalomas are formed by 
adrenal adenocarcinomas, and around 0.7–2.5% of cases are caused by metastasis 
from tumors elsewhere toward the adrenal [13, 14].
Size and some other radiology characteristics of the computed tomography and 
magnetic resonance imaging might help differentiating an adrenal benign lesion from a 
malign one, with consequent perioperative implications. Adrenal tumors with surgical 
indication are generally approached through laparoscopy. On the other hand, in cases 
when an adrenal adenocarcinoma is suspected, open surgery is preferable, especially 
for larger lesions (>10 cm), or for those that might expand to other organs [15].
There is a direct relationship between the size of the adrenal tumor and the 
potential for malignancy. Average size of an adrenal adenocarcinoma at diagnosis 
is 10–11 cm, whereas most benign adrenal tumors present a diameter smaller than 
5 cm [16].
Besides their larger size, malign adrenal tumors, in most cases, show on image 
exams as heterogeneous lesions, with irregular margins, suggestive calcifications, 
and a peripheral enhancement by intravenous contrast due to the core of the 
necrosis. Expansion toward other organs and lymph node involvement confirm 
malignancy.
Adrenal adenomas feature a profuse presence of lipids in their constitution. It is, 
therefore, very useful to assess the lipid contents by means of density calculation for 
differentiating adrenal tumors [15].
6.1 Computed tomography
The computed tomography is a very important exam in assessing adrenal tumors. 
At the phase with no contrast, a density calculus is used by means of the Hounsfield 
units (UH). Lesions with a <10 UH density have a high probability of being benign, 
whereas most adrenal adenocarcinomas present a >30 UH, which indicates low lipid 
content. Thus, tumors with density >10 UH demand further assessment.
Precision of diagnosis may be enhanced by the use of late stages of computed 
tomography with contrast and the “washout” calculation, which represents the 
fraction of contrast that is eliminated 10 min after administration. The finding 
of an average absolute “washout” of 50% after 10 min of contrast used in studies 
evidenced a 100% sensitivity and specificity for detection of adenomas in relation 
to adenocarcinomas, pheochromocytoma, and extra-adrenal metastases [17, 18].
All patients likely to be suffering from an adrenal adenocarcinoma should 
undergo a computed tomography of the thorax prior to surgery as any findings 
related to metastasis may alter the approach of treatment.
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6.2 Magnetic resonance imaging
Despite the fact that the computed tomography is the most important exam in 
assessing adrenal nodules, in some situations it is imperative to resort to a magnetic 
resonance imaging.
Analysis of conventional images weighted at T1 and T2 is the most frequently 
used technique. Adrenal adenocarcinomas present an isointense sign in relation to 
the T1 liver and enhanced intensity of sign at weighted sequences at T2 (Figure 4). 
Typically, they present as large lesions (>5.0 cm) at the moment of the diagnosis 
and may include necrosis, bleeding, and, frequently, calcification [19].
After administration of gadolinium, a slight increase of sign is noticed, as well 
as a swift washout of contrast, whereas malign lesions present a fast and striking 
increase of sign followed by a rather slow washout pattern [20].
Chemical shift imaging is a detection technique for the presence of lipids. 
Benign lesions show as relatively shiny at the in-phase images, and they present 
a dimmed sign at the out-of-phase ones. The majority of adenomas are slightly 
hypointense or isointense to the liver on T1-weighted images and slightly hyper-
intense or isointense on T2-weighted images. The utilization of chemical shift 
techniques (in-phase or out-of-phase GRE) allows the characterization of adenomas 
containing microscopic fat and water protons in a same voxel (Figure 5). On out-of-
phase images, the protons signal is null and results in signal loss as compared with 
in-phase images [21–24].
A magnetic resonance imaging may be superior to a computed tomography in 
the assessment of the vascular invasion, especially in terms of the inferior vena cava 
[25, 26].
6.3 Other resources of diagnosis per image
In patients whose characterization of lesion malignancy could not be carried out 
by a tomography or resonance, additional information could be obtained through 
fluorine-18 fluorodeoxyglucose positron emission tomography. Malignant lesions 
present a high collection rate of the radiotracer.
Metomidate binds itself specifically to Cyp11b cortical adrenal enzymes. It 
is used as a radiotracer at C-MTO PET, as it is capable of differentiating lesions 
originated at the adrenal cortical from the metastatic ones toward the adrenal [27].
Figure 4. 
Adrenal cortical carcinoma. Magnetic resonance imaging coronal T2-weighted FSE (A) and contrast-enhanced 
axial T1-weighted GRE (B) sequences demonstrate a large expansive lesion involving the right adrenal 
gland. The lesion shows heterogeneous pattern of impregnation by the contrast agent and areas of necrosis 
(hypersignal on T2-weighted sequences) (arrows).
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virilization [1]. For individuals that present such virilization or high concentrations 
of androgens, adrenalectomy may be indicated for controlling of hormones.
Estrogen-producing tumors are rare and they are generally malignant. In men, it 
may manifest through feminization with gynecomastia, decrease in libido, atrophy 
of testicles, whereas in women, it could manifest through breast sensitivity and 
bleedings [12]. In such cases, adrenalectomy may also be indicated.
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magnetic resonance imaging might help differentiating an adrenal benign lesion from a 
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indication are generally approached through laparoscopy. On the other hand, in cases 
when an adrenal adenocarcinoma is suspected, open surgery is preferable, especially 
for larger lesions (>10 cm), or for those that might expand to other organs [15].
There is a direct relationship between the size of the adrenal tumor and the 
potential for malignancy. Average size of an adrenal adenocarcinoma at diagnosis 
is 10–11 cm, whereas most benign adrenal tumors present a diameter smaller than 
5 cm [16].
Besides their larger size, malign adrenal tumors, in most cases, show on image 
exams as heterogeneous lesions, with irregular margins, suggestive calcifications, 
and a peripheral enhancement by intravenous contrast due to the core of the 
necrosis. Expansion toward other organs and lymph node involvement confirm 
malignancy.
Adrenal adenomas feature a profuse presence of lipids in their constitution. It is, 
therefore, very useful to assess the lipid contents by means of density calculation for 
differentiating adrenal tumors [15].
6.1 Computed tomography
The computed tomography is a very important exam in assessing adrenal tumors. 
At the phase with no contrast, a density calculus is used by means of the Hounsfield 
units (UH). Lesions with a <10 UH density have a high probability of being benign, 
whereas most adrenal adenocarcinomas present a >30 UH, which indicates low lipid 
content. Thus, tumors with density >10 UH demand further assessment.
Precision of diagnosis may be enhanced by the use of late stages of computed 
tomography with contrast and the “washout” calculation, which represents the 
fraction of contrast that is eliminated 10 min after administration. The finding 
of an average absolute “washout” of 50% after 10 min of contrast used in studies 
evidenced a 100% sensitivity and specificity for detection of adenomas in relation 
to adenocarcinomas, pheochromocytoma, and extra-adrenal metastases [17, 18].
All patients likely to be suffering from an adrenal adenocarcinoma should 
undergo a computed tomography of the thorax prior to surgery as any findings 
related to metastasis may alter the approach of treatment.
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6.2 Magnetic resonance imaging
Despite the fact that the computed tomography is the most important exam in 
assessing adrenal nodules, in some situations it is imperative to resort to a magnetic 
resonance imaging.
Analysis of conventional images weighted at T1 and T2 is the most frequently 
used technique. Adrenal adenocarcinomas present an isointense sign in relation to 
the T1 liver and enhanced intensity of sign at weighted sequences at T2 (Figure 4). 
Typically, they present as large lesions (>5.0 cm) at the moment of the diagnosis 
and may include necrosis, bleeding, and, frequently, calcification [19].
After administration of gadolinium, a slight increase of sign is noticed, as well 
as a swift washout of contrast, whereas malign lesions present a fast and striking 
increase of sign followed by a rather slow washout pattern [20].
Chemical shift imaging is a detection technique for the presence of lipids. 
Benign lesions show as relatively shiny at the in-phase images, and they present 
a dimmed sign at the out-of-phase ones. The majority of adenomas are slightly 
hypointense or isointense to the liver on T1-weighted images and slightly hyper-
intense or isointense on T2-weighted images. The utilization of chemical shift 
techniques (in-phase or out-of-phase GRE) allows the characterization of adenomas 
containing microscopic fat and water protons in a same voxel (Figure 5). On out-of-
phase images, the protons signal is null and results in signal loss as compared with 
in-phase images [21–24].
A magnetic resonance imaging may be superior to a computed tomography in 
the assessment of the vascular invasion, especially in terms of the inferior vena cava 
[25, 26].
6.3 Other resources of diagnosis per image
In patients whose characterization of lesion malignancy could not be carried out 
by a tomography or resonance, additional information could be obtained through 
fluorine-18 fluorodeoxyglucose positron emission tomography. Malignant lesions 
present a high collection rate of the radiotracer.
Metomidate binds itself specifically to Cyp11b cortical adrenal enzymes. It 
is used as a radiotracer at C-MTO PET, as it is capable of differentiating lesions 
originated at the adrenal cortical from the metastatic ones toward the adrenal [27].
Figure 4. 
Adrenal cortical carcinoma. Magnetic resonance imaging coronal T2-weighted FSE (A) and contrast-enhanced 
axial T1-weighted GRE (B) sequences demonstrate a large expansive lesion involving the right adrenal 
gland. The lesion shows heterogeneous pattern of impregnation by the contrast agent and areas of necrosis 
(hypersignal on T2-weighted sequences) (arrows).
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7. Conclusion
Patients diagnosed with adrenal lesions should undergo a thorough assessment 
of functioning in light of the possibility of malignancy.
Functioning adrenal tumors or those likely to be malignant should lead to surgi-
cal treatment.
Special care should be taken in preparation prior to adrenalectomy of patients 
that might suffer from functioning tumors or pheochromocytoma.
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Figure 5. 
Magnetic resonance imaging axial T1-weighted phase GRE (A) and axial out-of-phase sequences  
(B) demonstrate right adrenal lesions signal loss (arrows), allowing the diagnosis of microscopic lipid-rich 
adenoma.
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Abstract
Sacrococcygeal teratomas (SCT) represents a group tumors deriving from the 
primordial germ cells. It is the most common tumor affecting neonates, with a 
female to male ratio of almost 4:1.78. SCT are either benign (mature) or malignant 
(immature) with different outcome. With advancements in ultrasonography, more 
SCT are diagnosed prenatally. magnetic resonance imaging (MRI) is more accurate in 
describing the intrapelvic and abdominal extent of the tumor. Most fetal teratomas 
could be managed by planned delivery and postnatal surgery. The earlier the diagno-
sis and surgical intervention, the better the prognosis. A complete surgical excision 
of the tumor is necessary, including coccygectomy, to prevent recurrence. At the time 
of birth, most lesions are benign and surgical resection can be accomplished with 
relatively low morbidity and mortality. Recurrence is reported as 2–35% in patients 
with immature teratomas, tumor spillage, incomplete resection or failure to remove 
the coccyx. A long-term follow-up is required for any urinary or bowel dysfunction.
Keywords: sacrococcygeal, teratomas, surgery, children, tumor 
1. Introduction
Sacrococcygeal teratoma is the most common congenital neoplasm. The word “ter-
atoma” is derived from the Greek word “teratos” meaning monster. The first reported 
case was described on a cuneiform tablet dated approximately 2000 BC. Advances 
in antenatal imaging have let to prenatal detection of most SCTs and may avoid early 
mortality. Delayed presentation and presence of malignant elements continue to be 
poor prognostic factors, while surgical goal remains complete resection.
2. Background
Although rare, SCT is the most common tumor of the fetus and the newborn, 
with a reported prevalence of 0.25–0.28:10,000 live births. With more advance-
ments in US (ultrasonography), more SCT are diagnosed prenatally.
2.1 Etiology
SCT arises from pluripotent cells of Hense’s node that is present/located anterior 
to coccyx, a remnant of the primitive streak in the coccygeal region. The primitive 
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streak is a longitudinal ridge of ectodermal cells at the caudal end of the bilaminar 
embryonic disc. It consists of totipotent cells, which are able to transform into any 
type of cells. This structure determines the future craniocaudally axis of the embryo 
and demarcates the embryo into left and right halves. If totipotent cells of the 
primitive streak remain after the fourth week, these cells give rise to a SCT [1].
SCT is a relatively uncommon tumor affecting neonates, infants and children.
SCT represents a group of benign and malignant tumors deriving from the 
primordial germ cells. Pediatric germ cell tumors (GCTs) are neoplasms derived from 
primordial germ cells and may occur both inside the gonads and extragonadal organs. 
The five main histologic categories of GCTs are: dysgerminomas (in the ovary), 
seminomas (in the testes), teratomas, choriocarcinomas and endodermal sinus tumor 
(ESTS) or Yolk sac tumor. The most common site of extragonadal GCTs in the pediat-
ric population is the sacrococcygeal region and the most common type are teratomas.
The sacrococcygeal region is the most frequent location for teratomas, but 
teratomas may occur in almost any organ, tending to develop more commonly in 
midline or paraxial location and can be observed from the brain (cephalad) to the 
coccyx (caudal). Less common sites are the mediastinum, testes, ovary, retroperito-
neum, head [2, 3].
Females are affected more frequently with a female to male ratio of almost 
4:1.78. SCT are either mature, immature or malignant, composed of embryonic 
elements. A mature SCT is a benign tumor containing only mature components, 
while immature SCT contains immature tissues. SCT that contains malignant ele-
ments are considered to be malignant tumors. Mature and immature teratomas are 
considered as benign tumors and may undergo malignant transformation. At birth, 
the great majority of SCTs are benign. They can manifest malignant transformation 
with advanced age.
They appear as cystic tumors or solid. The cystic may be filled with serous fluid, 
mucoid or sebaceous material, or even cerebrospinal fluid. Virtually any tissue 
can be present in a SCT. Neuroglial tissue, skin, respiratory and enteric epithelium 
cartilage, smooth muscle and striated muscle fibers are the most common elements 
found. Also bone, pancreatic tissue, choroid plexus and adrenal tissues are less 
commonly identified.
2.2 Classification
Size of a SCT (average 8 cm diameter, range 1–30 cm) does not predict its 
biological behavior. Altman et al. defined the size of SCT as follows:
Small: as 2–5 cm diameter
Moderate: 5–10 cm
Large: >10 cm.
Antenatal diagnosis is important to avoid complications during delivery. Fetal 
US and MRI are the mainstay of antenatal diagnosis of SCT. MRI is more accurate 
in describing the intrapelvic and abdominal extent of the tumor and provides more 
information on compression of adjacent organs. Prenatal assessment of the fetus 
is critical for counseling the parents and planning surgical options. Because of 
acoustic shadowing by the fetal pelvic bones, US cannot always define the extent of 
SCT. Fetal MRI has been successfully performed to evaluate anatomy, content and 
extent of the tumor, but just a few small cases series have been published yet.
SCT arise from the base of the coccyx and may continuously grow in the poste-
rior direction forming an external protrusion, or in the anterior direction, dissect-
ing and distorting surrounding structures such as the rectum, vagina and bladder, 
but without invading them. Based on this morphologic characteristic, Altman et al. 
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have been defined The American Academy of Pediatrics Surgical Section (APPSS) 
classification [3–5]:
Type I: predominantly external with minimal presacral component—45.8%
Type II: present externally, but with significant intrapelvic extension—34%
Type III: apparent externally but predominantly a pelvic mass extending into the 
abdomen—8.6%
Type IV: presacral mass with no external presentation—9.6%.
2.3 Histology
SCT are graded histologically as follows:
Grade 0—tumor contains only mature tissue
Grade 1—tumor contains rare foci of immature tissues
Grade 2—tumor contains moderate quantities of immature tissues
Grade 3—tumor contains large quantities of immature tissue with or without 
malignant yolk sac elements.
3. Diagnosis
3.1 Intrauterine diagnosis
The majority of SCT present between the 22nd and the 34th week of gestation. 
The diagnosis of SCT on routine US is associated with a greater than expected inci-
dence of prenatal and perinatal complications. Close antenatal follow up is needed 
to optimize patient counselling and treatment in the presence of a completely solid 
tumor and the onset of polyhydramnios. A poor outcome is usually correlated with 
placentomegaly, cardiomegaly or non-immune hydrops fetalis.
3.2 Associated anomalies
Associated congenital malformations are observed in 12–15% of cases and 
occur more frequently with presacral tumors. The incidence of various congenital 
malformations associated with SCT ranges from 5 to 26%. Of these, anorectal and 
genital malformations are most commonly. A growing SCT during the first weeks of 
embryonic life will encroach between the layers of the cloacal membrane and pre-
vent descent and fusion of the urorectal septum to the cloacal membrane, resulting 
in a high anorectal malformation with a rectourethral or rectovestibular fistula. The 
presence of SCT in the same period of time (47th weeks), when cloaca is subdivided 
by the urorectal septum to form the anorectal canal and the primitive urogenital 
sinus, could prevent fusion of the genital folds, resulting in a bifid scrotum or 
hypospadias. The most commonly observed anorectal defects are: imperforate anus, 
anorectal stenosis and common vertebral anomalies are: sacral hemivertebrae, 
absence of the sacrum and coccyx [6].
Other associated anomalies include spinal dysraphism, sacral agenesis, disloca-
tion of the hips and meningocele. Rarely, gastrointestinal or cardiac defects are 
associated with SCT.
Currarino triad represents association of anorectal malformation, sacral dyspla-
sia and presacral mass. Delay in diagnosis of the presacral lesion is common because 
a rectal examination may not be possible in many cases with anorectal stenosis. 
Presenting symptoms in some of these unusual cases include perirectal abscess or 
fistula in ano (Figure 1).
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streak is a longitudinal ridge of ectodermal cells at the caudal end of the bilaminar 
embryonic disc. It consists of totipotent cells, which are able to transform into any 
type of cells. This structure determines the future craniocaudally axis of the embryo 
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seminomas (in the testes), teratomas, choriocarcinomas and endodermal sinus tumor 
(ESTS) or Yolk sac tumor. The most common site of extragonadal GCTs in the pediat-
ric population is the sacrococcygeal region and the most common type are teratomas.
The sacrococcygeal region is the most frequent location for teratomas, but 
teratomas may occur in almost any organ, tending to develop more commonly in 
midline or paraxial location and can be observed from the brain (cephalad) to the 
coccyx (caudal). Less common sites are the mediastinum, testes, ovary, retroperito-
neum, head [2, 3].
Females are affected more frequently with a female to male ratio of almost 
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2.2 Classification
Size of a SCT (average 8 cm diameter, range 1–30 cm) does not predict its 
biological behavior. Altman et al. defined the size of SCT as follows:
Small: as 2–5 cm diameter
Moderate: 5–10 cm
Large: >10 cm.
Antenatal diagnosis is important to avoid complications during delivery. Fetal 
US and MRI are the mainstay of antenatal diagnosis of SCT. MRI is more accurate 
in describing the intrapelvic and abdominal extent of the tumor and provides more 
information on compression of adjacent organs. Prenatal assessment of the fetus 
is critical for counseling the parents and planning surgical options. Because of 
acoustic shadowing by the fetal pelvic bones, US cannot always define the extent of 
SCT. Fetal MRI has been successfully performed to evaluate anatomy, content and 
extent of the tumor, but just a few small cases series have been published yet.
SCT arise from the base of the coccyx and may continuously grow in the poste-
rior direction forming an external protrusion, or in the anterior direction, dissect-
ing and distorting surrounding structures such as the rectum, vagina and bladder, 
but without invading them. Based on this morphologic characteristic, Altman et al. 
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have been defined The American Academy of Pediatrics Surgical Section (APPSS) 
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3.3 Clinical presentation
Most external tumors are asymptomatic, with the exception of the presence of a 
visible exophytic large mass at the sacral region with occasional surface ulceration 
and hemorrhage and with anus displaced anteriorly (Figure 2). Sometimes, rupture 
of the tumor may occur as a result of a difficult delivery. Pelvic tumors or tumors 
that extend into the abdominal cavity may present with compression of the rectum 
or recto-sigmoid and urinary tract obstruction (constipation, frequent stools, 
obstruction of the bladder neck).
3.4 Diagnostic tools
Except for clinical examination, there are a variety of radiographic studies that 
can help. Plain X-Ray may show the presence of calcification within the tumor and 
anterior displacement of the rectum by the tumor. The sacrum may appear abnor-
mal (such as hemivertebrae, agenesis).
Computer tomography (CT) or MRI of the pelvis with intravenous contrast 
material may reveal urinary tract displacement or obstruction and outlines the 
extent of the tumor more accurately. MRI is also a useful diagnosis of spinal cord 
extension of tumor (Figure 3).
A chest X-Ray or CT thoracic scan is obtaining to rule out the presence of 
pulmonary metastases.
Malignant SCT may have elevated tumor markers. The most commonly pro-
duced tumor marker is AFP (alpha-fetoprotein) because yolk sac components are 
the most common malignant elements. Other malignant elements may produce beta 
HCG (human chorionic gonadotropin). Serum AFP and beta HCG should be evalu-
ated at the initial diagnostic work-up and assessed to monitor tumor relapse during 
the follow up period. The use of AFP as a tumor marker is well established and 
persistent, elevated level may indicate a residual tumor, recurrence or malignant 
degeneration. Because AFP is produced by fetal liver and fetal gastrointestinal tract, 
Figure 1. 
Currarino triad in a female patient with SCT—MRI. Red arrow points the SCT. The girl presented with 
imperforate anus, recto-vestibular fistula and SCT was misdiagnosed until MRI.
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its level is normally elevated in the first 8 months of life and after that age it rapidly 
falls to normal adult level (10 ng/ml). The mean time required for AFP to normalize 
after SCT resection is about 9 months [7, 8].
The differential diagnosis of SCT include rectal duplication, meningocele, 
lipoma, chordoma, epidermoid cyst, neuroblastoma.
Figure 2. 
SCT type II in a newborn girl. Large mass visible in sacral region, with displacement of anal orifice.
Figure 3. 
Type II SCT with intrapelvic component—MRI.
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Fetal MRI is a powerful addition to the prenatal evaluation of fetuses with 
SCT. Due to the fact that, in most cases, neonatal surgery is required soon after 
cesarean section, the anatomic details of tumor extent and involvement of adjacent 
structures may affect the surgical approach. Patients with significant intrapelvic 
extension of the tumor may need a combined abdominoperineal approach to 
control the blood supply and achieve complete resection. All these may contribute 
to avoid resection-related complications during surgery [9] (Figure 4).
Monitoring for fetal distress during pregnancy is very important. Some large 
tumors have a very high blood flow that causes a shift in blood flow away, producing 
fetal hydrops. Other possible complications are bleeding inside the tumor, polyhy-
dramnios and preterm labor. A rare condition is called “mirror syndrome” where 
the mother mirrors the baby’s sickness, leading to fluid retention, preeclampsia, 
high blood pressure, heart failure [10, 11].
4.2 Surgical management
Most fetal teratomas could be managed by planned delivery and postnatal 
surgery. The earlier the diagnosis and surgical intervention, the better the progno-
sis. A complete surgical excision of the tumor including coccygectomy is necessary, 
in order to avoid recurrence. A long term observation and follow-up is required for 
any urinary or bowel dysfunction.
Mature teratomas should not recur, if complete surgical excision and coccy-
gectomy were achieved properly. Recurrence is reported in literature, as 2–35%, in 
patients with immature teratomas operated after the age of 5 months and is related 
to tumor spillage or incomplete excision.
At the time of birth, most lesions are benign and surgical resection can be 
accomplished with relatively low morbidity and mortality. The incidence of 
Figure 4. 
Antenatal diagnosis of SCT using MRI and measurements.
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malignancy in SCT is increasing with age. Failure to remove the coccyx results in 
30–40% recurrence rate, with a higher probability of malignancy. Alpha fetoprotein 
may be used to detect early occurrence of malignancy.
Management of SCT depends on fetal lung maturation and presence of placental 
enlargement and/or fetal hydrops. When maturity of fetal lung without placental 
enlargement and/or hydrops fetalis, planned cesarean section is indicated. Some 
authors recommend preventive early delivery by cesarean section when the tumor 
exceeds the diameter of 5 cm, to avoid complications such as rupture and hemor-
rhage. The primary treatment of SCT is early surgical resection with complete exci-
sion of the coccyx. Early surgical intervention is associated with better prognosis. 
The surgical approach depends on the degree of pelvic extension. Posterior sacral 
approach is recommended in type I and II, and combined abdominal and posterior 
sacral approaches in type III and IV. The technique of wide resection of benign 
lesions with coccygectomy is helpful in preventing recurrence and has changed 
little over the last four decades.
The goals of surgical resection of an SCT are:
• Complete resection of the tumor
• Removal of the coccyx
• Reconstruction of the pelvic floor and ano-rectal sphincter
• Acceptable cosmetic appearance
After inserting a urinary catheter, the patient is placed in the prone jack-knife 
position. A V-shaped incision is made at the superior margin of the tumor. It is 
important to identify the course of the anus by placing a tube in the anal canal. 
After raising skin flaps, the muscles are dissected from the tumor which must be 
resected with the coccyx, after ligation of its main blood supply, which are middle 
sacral artery or branches from the hypogastric arteries [4, 7, 12].
Figure 5. 
Large SCT in a newborn—preoperative. SCT represents more than 50% of birthweight, with visible  
ulceration of the skin.
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The multiorgan involvement makes the anesthetic management challenging. 
Prematurity and hypothermia are risk factors for coagulopathy and can lead to fatal 
consequences. Management of intraoperative bleeding and early extubation are 
good outcome predictors [5, 13, 14] (Figure 5).
Patients with malignant SCT are managed after surgery with irradiation if 
residual disease is present, and chemotherapy. Most tumors have a plane of dis-
section and can be removed easily. It is safer and recommended to catheterize the 
bladder to keep it away from the tumor and place a large rubber catheter in rectum 
for identification. Levator ani muscles are often stretched over tumor and should 
be reconstructed after tumor is excised. Drainage is necessary as there is a large raw 
area and collections should be avoided (Figure 6).
Preservation of the autonomous nerve supply to the bladder and rectum may be 
difficult. Therefore, postoperative complications (31%) that may be expected are 
bladder dysfunction, incontinence for feces and dysesthesia. The main postopera-
tive early complication is wound infection because of the proximity to the anus and 
the skin flaps that may be needed.
5. Conclusions
SCT is a common neonatal neoplasm. Antenatal diagnosis is essential, for 
avoiding complications and high morbidity, mortality. Delivery in a tertiary center 
by cesarean section, when needed, should be emphasized. Early diagnosis and 
complete resection of the tumor with removal of the coccyx is associated with good 
prognosis.
Figure 6. 
Same newborn—postoperative view, after removal of SCT.
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